{"id":34208,"date":"2022-09-16T16:42:16","date_gmt":"2022-09-16T08:42:16","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=34208"},"modified":"2025-11-15T15:30:07","modified_gmt":"2025-11-15T07:30:07","slug":"ampicillin-sodium-cas-69-52-3-apexbio-%e8%b2%a8%e8%99%9fa2510","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=34208","title":{"rendered":"\u5b89\u6bd4\u897f\u6797Ampicillin sodium | CAS# 69-52-3 APExBIO \u8ca8\u865fA2510"},"content":{"rendered":"

\u03b2-\u5167\u91af\u80fa\u985e\u6297\u751f\u7d20\u7cfb\u5217\u5546\u54c1->><\/span><\/span>\u5b89\u6bd4\u897f\u6797Ampicillin sodium<\/span><\/span><\/strong><\/p>\n

APExBIO Technology LLC \u662f\u4e00\u5bb6\u9818\u5148\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291 (Small Molecule Inhibitors)\/\u6d3b\u5316\u5291(Activators)\u3001\u5316\u5408\u7269\u5eab( Compound Libraries)\u3001\u80dc\u80bd(Peptides)\u3001\u6aa2\u6e2c\u8a66\u5291\u76d2(Assay Kits)\u3001\u87a2\u5149\u6a19\u8a18(Fluorescent Label)\u3001\u9176(Enzymes)\u3001\u4fee\u98fe\u6838\u82f7\u9178(Modified Nucleotides)\u3001mRNA \u5408\u6210\u4ee5\u53ca\u5404\u7a2e\u5206\u5b50\u751f\u7269\u5b78\u5de5\u5177\u7684\u4f9b\u61c9\u5546\u3002APExBIO\u63d0\u4f9b\u5ee3\u6cdb\u7684\u7522\u54c1\u7dda\uff0c\u6db5\u84cb 20 \u591a\u500b\u4e0d\u540c\u7684\u7814\u7a76\u9818\u57df\uff0c\u4f8b\u5982\u764c\u75c7(cancer)\u3001\u514d\u75ab\u5b78(immunology)\u3001\u795e\u7d93\u79d1\u5b78(neurosciences)\u3001\u7d30\u80de\u51cb\u4ea1(apoptosis)\u548c\u8868\u89c0\u907a\u50b3\u5b78(epigenetics)\u7b49\u3002\u516c\u53f8\u7e3d\u90e8\u4f4d\u65bc\u7f8e\u570b\u5fb7\u5dde\u4f11\u58eb\u9813USA (Houston, Texas)\uff0c\u81f4\u529b\u65bc\u670d\u52d9\u5168\u7403\u5ba2\u6236\u3002\u9ad8\u5ea6\u91cd\u8996\u7522\u54c1\u54c1\u8cea\u3002\u6240\u6709\u7522\u54c1\u5747\u9075\u5faa\u56b4\u683c\u7684\u751f\u7522\u6307\u5357\uff0c\u4e26\u9644\u6709\u5206\u6790\u8b49\u66f8\u3001HPLC\u3001\u8cea\u8b5c(Mass Spectrum)\u548cHMNR\u4ee5\u53ca\u9ad4\u5916\u9a57\u8b49(in vitro validation)\u3002 APExBIO\u7522\u54c1\u5df2\u88ab\u300aNature\u300b\u3001\u300aCell\u300b\u548c\u300aScience\u300b\u7b49\u773e\u591a\u9802\u7d1a\u540c\u884c\u8a55\u5be9\u671f\u520a\u5f15\u7528\u3002>>\u66f4\u591aAPExBio\u5546\u54c1<\/span><\/strong><\/em><\/span><\/a><\/p>\n

<\/p>\n

\u5b89\u6bd4\u897f\u6797Ampicillin sodium | CAS# 69-52-3 APExBIO\u00a0 \u8ca8\u865fA2510<\/span><\/strong><\/a><\/span><\/p>\n

\"Ampicillin<\/p>\n

Ampicillin sodium is a competitive inhibitor of the enzyme transpeptidase with IC50 value of 1.8 \u03bcg\/ml [1].<\/p>\n

\u5b89\u6bd4\u897f\u6797(Ampicillin)\u662f\u4e00\u7a2e\u9176\u8f49\u80bd\u9176\u7684\u7af6\u722d\u6027\u6291\u5236\u5291\uff0cIC50 \u503c\u70ba 1.8 \u03bcg\/ml [1]\u3002<\/p>\n

\u5b89\u6bd4\u897f\u6797(Ampicillin)\u662f\u4e00\u7a2e\u03b2-\u5167\u91af\u80fa\u985e\u6297\u751f\u7d20(\u03b2-lactam antibiotic)\uff0c\u901a\u904e\u6291\u5236\u8f49\u80bd\u9176\u53cd\u61c9(transpeptidase reactions)\u4f86\u6bba\u6b7b\u7d30\u83cc\u3002\u8f49\u80bd\u9176(Transpeptidase)\u53c3\u8207\u7d30\u80de\u58c1\u751f\u7269\u5408\u6210(cell wall biosynthesis)\u7684\u6700\u5f8c\u968e\u6bb5\uff0c\u5c0d\u5176\u7684\u6291\u5236\u6700\u7d42\u5c0e\u81f4\u7d30\u80de\u88c2\u89e3(cell lysis) [1]\u3002\u5728\u4e59\u919a\u8655\u7406\u7684\u5927\u8178\u687f\u83cc146\u7d30\u80de\u4e2d\uff0c\u5b89\u6bd4\u897f\u6797(Ampicillin)\u5728\u4f4e\u65bc0.5 \u03bcg\/ml\u7684\u6fc3\u5ea6\u4e0b\u5c0d\u8f49\u80bd\u9176\u53cd\u61c9(transpeptidase reaction)\u6c92\u6709\u660e\u986f\u7684\u6291\u5236\u4f5c\u7528\uff0c\u4f46\u57281.8 \u03bcg\/ml\u7684\u6fc3\u5ea6\u4e0b\u8868\u73fe\u51fa50%\u7684\u6291\u5236\u4f5c\u7528\u3002\u5728\u5927\u8178\u687f\u83cc 146 \u7d30\u80de\u4e2d\uff0c\u5b89\u6bd4\u897f\u6797(Ampicillin)\u7684\u6700\u4f4e\u6291\u83cc\u6fc3\u5ea6 (MIC) \u70ba 3.1 \u03bcg\/ml [1]\u3002\u5728\u5927\u8178\u687f\u83cc(E. coli)<\/em>\u548c\u50b7\u5bd2\u6c99\u9580\u6c0f\u83cc\u4e2d\uff0c\u6fc3\u5ea6\u63a5\u8fd1 MIC \u503c\u7684\u5b89\u6bd4\u897f\u6797(Ampicillin)\u548c Epicillin \u6bba\u6b7b\u7d30\u83cc\u7684\u901f\u5ea6\u6bd4\u963f\u83ab\u897f\u6797\u6162 [2]\u3002\u5728\u5be6\u9a57\u6027\u5c0f\u9f20\u611f\u67d3\u4e2d\uff0c\u4ee5 0.2 ml\/20 g \u7684\u5291\u91cf\u53e3\u670d\u6216\u76ae\u4e0b\u6ce8\u5c04\u5b89\u6bd4\u897f\u6797(Ampicillin)\u5c0d\u5927\u591a\u6578\u611f\u67d3\u7684\u6cbb\u7642\u6548\u679c\u660e\u986f\u512a\u65bc Epicillin \u548c Amoxycillin [2]\u3002<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Storage<\/td>\nStore at -20\u00b0C<\/td>\n<\/tr>\n
M.Wt<\/td>\n371.4<\/td>\n<\/tr>\n
Cas No.<\/td>\n69-52-3<\/td>\n<\/tr>\n
Formula<\/td>\nC16<\/sub>H18<\/sub>N3<\/sub>NaO4<\/sub>S<\/td>\n<\/tr>\n
Solubility<\/td>\n\u226518.57 mg\/mL in H2O; \u226573.6 mg\/mL in DMSO; \u226575.2 mg\/mL in EtOH<\/td>\n<\/tr>\n
Chemical Name<\/td>\nsodium;(2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate<\/td>\n<\/tr>\n
SDF<\/td>\nDownload SDF<\/a><\/td>\n<\/tr>\n
Canonical SMILES<\/td>\nCC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)[O-])C.[Na+]<\/td>\n<\/tr>\n
Shipping Condition<\/td>\nShip with blue ice, or upon other requests.<\/td>\n<\/tr>\n
General tips<\/td>\nFor obtaining a higher solubility, please warm the tube at 37\u00b0C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

APExBIO\u53f0\u7063\u4ee3\u7406\u5546:\u00a0 <\/span><\/span><\/strong><\/span><\/a>https:\/\/www.apexbt.com\/<\/span><\/span><\/a><\/span><\/p>\n

APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n

<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Cat#<\/td>\nProduct Name<\/td>\n<\/tr>\n
A8743<\/td>\nSYBR Safe DNA Gel Stain<\/td>\n<\/tr>\n
A6001<\/td>\n3X (DYKDDDDK) Peptide<\/td>\n<\/tr>\n
K1018<\/td>\nCell Counting Kit-8 (CCK-8)<\/td>\n<\/tr>\n
A1902<\/td>\nZ-VAD-FMK<\/td>\n<\/tr>\n
A3008<\/td>\nY-27632 dihydrochloride<\/td>\n<\/tr>\n
A6002<\/td>\nDYKDDDDK tag Peptide<\/td>\n<\/tr>\n
B8362<\/td>\n2’3′-cGAMP (sodium salt)<\/td>\n<\/tr>\n
F4002<\/td>\nPhos binding reagent (Phosbind) acrylamide<\/td>\n<\/tr>\n
A8011<\/td>\nBiotin-tyramide<\/td>\n<\/tr>\n
A2585<\/td>\nMG-132<\/td>\n<\/tr>\n
F4005<\/td>\nPrestained Protein Marker (Triple color, EDTA free, 10-250 kDa)<\/td>\n<\/tr>\n
B1274<\/td>\nAP20187<\/td>\n<\/tr>\n
K1007<\/td>\nProtease Inhibitor Cocktail(EDTA-Free,100X in DMSO)<\/td>\n<\/tr>\n
B8226<\/td>\nInstaBlue Protein Stain Solution<\/td>\n<\/tr>\n
A3011<\/td>\nCHIR-99021 (CT99021)<\/td>\n<\/tr>\n
A3007<\/td>\nABT-263 (Navitoclax)<\/td>\n<\/tr>\n
B1524<\/td>\nErastin<\/td>\n<\/tr>\n
B6055<\/td>\nTCEP hydrochloride<\/td>\n<\/tr>\n
K1031<\/td>\nPhusion high-fidelity DNA polymerase<\/td>\n<\/tr>\n
B1387<\/td>\n(-)-Blebbistatin<\/td>\n<\/tr>\n
B4664<\/td>\nT-5224<\/td>\n<\/tr>\n
A8183<\/td>\nTrichostatin A (TSA)<\/td>\n<\/tr>\n
B3699<\/td>\nISRIB (trans-isomer)<\/td>\n<\/tr>\n
A1910<\/td>\nBromodomain Inhibitor, (+)-JQ1<\/td>\n<\/tr>\n
B1293<\/td>\nY-27632<\/td>\n<\/tr>\n
A8167<\/td>\nRapamycin (Sirolimus)<\/td>\n<\/tr>\n
A7024<\/td>\nHOAt<\/td>\n<\/tr>\n
A7025<\/td>\nHOBt (anhydrous)<\/td>\n<\/tr>\n
A8331<\/td>\nBleomycin Sulfate<\/td>\n<\/tr>\n
A4333<\/td>\nCPI-613<\/td>\n<\/tr>\n
K1070<\/td>\n2X SYBR Green qPCR Master Mix<\/td>\n<\/tr>\n
A8005<\/td>\nSulfo-NHS-SS-Biotin<\/td>\n<\/tr>\n
B4653<\/td>\nBV6<\/td>\n<\/tr>\n
B5965<\/td>\nTamoxifen<\/td>\n<\/tr>\n
A1901<\/td>\nQ-VD-OPh hydrate<\/td>\n<\/tr>\n
A8950<\/td>\nUM 171<\/td>\n<\/tr>\n
K1046<\/td>\nRNase Inhibitor, Murine<\/td>\n<\/tr>\n
A3317<\/td>\nClozapine N-oxide (CNO)<\/td>\n<\/tr>\n
A2614<\/td>\nBortezomib (PS-341)<\/td>\n<\/tr>\n
A8003<\/td>\nSulfo-NHS-LC-Biotin<\/td>\n<\/tr>\n
A4154<\/td>\nOlaparib (AZD2281, Ku-0059436)<\/td>\n<\/tr>\n
A8012<\/td>\nBiotin-XX Tyramide Reagent<\/td>\n<\/tr>\n
K1101<\/td>\nPreScission Protease (PSP)<\/td>\n<\/tr>\n
A8627<\/td>\nBafilomycin A1<\/td>\n<\/tr>\n
A8001<\/td>\nSulfo-NHS-Biotin<\/td>\n<\/tr>\n
A3017<\/td>\nDasatinib (BMS-354825)<\/td>\n<\/tr>\n
A2576<\/td>\nE-64<\/td>\n<\/tr>\n
K1051<\/td>\nCy3 TSA Fluorescence System Kit<\/td>\n<\/tr>\n
K1034<\/td>\n2X Taq PCR Master Mix (with dye)<\/td>\n<\/tr>\n
B7972<\/td>\nPseudo-UTP<\/td>\n<\/tr>\n
A8173<\/td>\nRomidepsin (FK228, depsipeptide)<\/td>\n<\/tr>\n
A4219<\/td>\nBirinapant (TL32711)<\/td>\n<\/tr>\n
A4371<\/td>\nFerrostatin-1 (Fer-1)<\/td>\n<\/tr>\n
A8200<\/td>\nDAPT (GSI-IX)<\/td>\n<\/tr>\n
A8249<\/td>\nSB 431542<\/td>\n<\/tr>\n
K1008<\/td>\nProtease Inhibitor Cocktail (EDTA-Free, 200X in DMSO)<\/td>\n<\/tr>\n
A3133<\/td>\nA 83-01<\/td>\n<\/tr>\n
A8192<\/td>\nStaurosporine<\/td>\n<\/tr>\n
B1054<\/td>\nResiquimod (R-848)<\/td>\n<\/tr>\n
A3018<\/td>\nTrametinib (GSK1120212)<\/td>\n<\/tr>\n
A8184<\/td>\nAICAR<\/td>\n<\/tr>\n
K1025<\/td>\nDirect Mouse Genotyping Kit<\/td>\n<\/tr>\n
A2606<\/td>\nEpoxomicin<\/td>\n<\/tr>\n
A6006<\/td>\nHexa His tag peptide<\/td>\n<\/tr>\n
A4393<\/td>\nPaclitaxel (Taxol)<\/td>\n<\/tr>\n
A8315<\/td>\nNU7441 (KU-57788)<\/td>\n<\/tr>\n
A4213<\/td>\nNecrostatin-1<\/td>\n<\/tr>\n
A8885<\/td>\nRo 3306<\/td>\n<\/tr>\n
L1021<\/td>\nDiscoveryProbe\u2122 FDA-approved Drug Library<\/td>\n<\/tr>\n
B1464<\/td>\nKPT-330<\/td>\n<\/tr>\n
A8815<\/td>\nSM-164<\/td>\n<\/tr>\n
B4879<\/td>\nBlasticidin S HCl<\/td>\n<\/tr>\n
A8793<\/td>\nN3-kethoxal<\/td>\n<\/tr>\n
K1047<\/td>\nHyperScribe\u2122 T7 High Yield RNA Synthesis Kit<\/td>\n<\/tr>\n
A6004<\/td>\nInfluenza Hemagglutinin (HA) Peptide<\/td>\n<\/tr>\n
B1036<\/td>\nMLN4924<\/td>\n<\/tr>\n
A8178<\/td>\nPanobinostat (LBH589)<\/td>\n<\/tr>\n
A3963<\/td>\nA-769662<\/td>\n<\/tr>\n
A3847<\/td>\nSU5416<\/td>\n<\/tr>\n
B3252<\/td>\nDorsomorphin (Compound C)<\/td>\n<\/tr>\n
B4758<\/td>\nBAPTA-AM<\/td>\n<\/tr>\n
A2513<\/td>\nGeneticin, G-418 Sulfate<\/td>\n<\/tr>\n
B6004<\/td>\nPX-478 2HCl<\/td>\n<\/tr>\n
A8955<\/td>\nZ-YVAD-FMK<\/td>\n<\/tr>\n
A8193<\/td>\nABT-737<\/td>\n<\/tr>\n
B2083<\/td>\nCaspofungin Acetate<\/td>\n<\/tr>\n
A8002<\/td>\nNHS-Biotin<\/td>\n<\/tr>\n
A8337<\/td>\nCX-5461<\/td>\n<\/tr>\n
A8312<\/td>\nTorin 1<\/td>\n<\/tr>\n
A2570<\/td>\nLeupeptin, Microbial<\/td>\n<\/tr>\n
K2170<\/td>\nAlanine Aminotransferase (ALT or SGPT) Activity Colorimetric\/Fluorometric Assay Kit<\/td>\n<\/tr>\n
A4381<\/td>\nFK866 (APO866)<\/td>\n<\/tr>\n
B2143<\/td>\nTacrolimus (FK506)<\/td>\n<\/tr>\n
A2571<\/td>\nPepstatin A<\/td>\n<\/tr>\n
k1072<\/td>\nFirst-Strand cDNA Synthesis Kit<\/td>\n<\/tr>\n
A3003<\/td>\nMDV3100 (Enzalutamide)<\/td>\n<\/tr>\n
B5997<\/td>\nDyngo-4a<\/td>\n<\/tr>\n
A3742<\/td>\nPyridostatin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

APExBIO\u53f0\u7063\u4ee3\u7406\u5546<\/a><\/p>\n

APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
A3477<\/td>\nHOKU-81<\/td>\n58020-43-2<\/td>\n98.00%<\/td>\nBronchodilators,metabolite of tulobuterol<\/td>\n<\/tr>\n
A3478<\/td>\nHydroxyfasudil<\/td>\n105628-72-6<\/td>\n98.00%<\/td>\nRho-kinase inhibitor and vasodilator<\/td>\n<\/tr>\n
A3479<\/td>\nHydroxyfasudil hydrochloride<\/td>\n155558-32-0<\/td>\n98.71%<\/td>\nRho-kinase inhibitor and vasodilator<\/td>\n<\/tr>\n
A3481<\/td>\nIbutamoren Mesylate<\/td>\n159752-10-0<\/td>\n98.00%<\/td>\nGrowth hormone (GH) secretagogue<\/td>\n<\/tr>\n
A3482<\/td>\nIcotinib Hydrochloride<\/td>\n1204313-51-8<\/td>\n98.00%<\/td>\nEGFR inhibitor,potent and specific<\/td>\n<\/tr>\n
A3483<\/td>\nIDO inhibitor 1<\/td>\n1204669-37-3<\/td>\n99.83%<\/td>\nIndoleamine-2,3-dioxygenase inhibitor<\/td>\n<\/tr>\n
A3484<\/td>\nIguratimod<\/td>\n123663-49-0<\/td>\n98.00%<\/td>\nCOX-2 inhibitor,inhibits IL-1,IL-6,IL-8 and tumour necrosis factor.<\/td>\n<\/tr>\n
A3485<\/td>\nIKK-2 inhibitor VIII<\/td>\n406209-26-5<\/td>\n98.00%<\/td>\nIKK-2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3486<\/td>\nIKK-3 Inhibitor<\/td>\n862812-98-4<\/td>\n98.00%<\/td>\nIKK-3 Inhibitor<\/td>\n<\/tr>\n
A3487<\/td>\nImatinib hydrochloride<\/td>\n862366-25-4<\/td>\n98.00%<\/td>\nV-Abl\/c-Kit\/PDGFR inhibitor<\/td>\n<\/tr>\n
A3492<\/td>\nINCB 3284 dimesylate<\/td>\n887401-93-6<\/td>\n98.00%<\/td>\nHCCR2 antagonist<\/td>\n<\/tr>\n
A3493<\/td>\nINCB024360 analogue<\/td>\n914471-09-3<\/td>\n99.81%<\/td>\npotent and selective inhibitor of IDO1<\/td>\n<\/tr>\n
A3494<\/td>\nINCB3344<\/td>\n1262238-11-8<\/td>\n98.01%<\/td>\nCCR2 chemokine receptor antagonist<\/td>\n<\/tr>\n
A3495<\/td>\nINCB8761(PF-4136309)<\/td>\n1341224-83-6<\/td>\n98.00%<\/td>\nCCR2 Antagonist,potent and selective<\/td>\n<\/tr>\n
A3496<\/td>\nIndacaterol<\/td>\n312753-06-3<\/td>\n98.00%<\/td>\n\u03b22-agonist<\/td>\n<\/tr>\n
A3498<\/td>\nInolitazone<\/td>\n223132-37-4<\/td>\n98.00%<\/td>\nPPARgamma agonist<\/td>\n<\/tr>\n
A3499<\/td>\nInolitazone dihydrochloride<\/td>\n223132-38-5<\/td>\n98.00%<\/td>\nPPAR\u03b3 agonist,high-affinity and novel<\/td>\n<\/tr>\n
A3500<\/td>\nIRAK inhibitor 1<\/td>\n1042224-63-4<\/td>\n98.11%<\/td>\nIRAK-4 inhibitor<\/td>\n<\/tr>\n
A3501<\/td>\nIRAK inhibitor 2<\/td>\n928333-30-6<\/td>\n98.00%<\/td>\nIRAK inhibitor<\/td>\n<\/tr>\n
A3502<\/td>\nIRAK inhibitor 3<\/td>\n1012343-93-9<\/td>\n98.00%<\/td>\nIRAK inhibitor<\/td>\n<\/tr>\n
A3503<\/td>\nIRAK inhibitor 4<\/td>\n1012104-68-5<\/td>\n98.00%<\/td>\nIRAK inhibitor<\/td>\n<\/tr>\n
A3504<\/td>\nIRAK inhibitor 6<\/td>\n1042672-97-8<\/td>\n99.90%<\/td>\nIRAK-4 inhibitor<\/td>\n<\/tr>\n
A3505<\/td>\nIRAK-1-4 Inhibitor I<\/td>\n509093-47-4<\/td>\n98.17%<\/td>\nIRAK-1\/4 inhibitor<\/td>\n<\/tr>\n
A3506<\/td>\nIsobavachalcone<\/td>\n20784-50-3<\/td>\n98.00%<\/td>\nDiverse biological activity compound<\/td>\n<\/tr>\n
A3507<\/td>\nIstaroxime<\/td>\n203737-93-3<\/td>\n98.00%<\/td>\nNa+\/K+ ATPase inhibitor<\/td>\n<\/tr>\n
A3508<\/td>\nIstaroxime hydrochloride<\/td>\n374559-48-5<\/td>\n98.00%<\/td>\nInhibitor of Na+\/K+ ATPase<\/td>\n<\/tr>\n
A3510<\/td>\nIvacaftor benzenesulfonate<\/td>\n1134822-09-5<\/td>\n99.90%<\/td>\nCFTR Potentiator<\/td>\n<\/tr>\n
A3511<\/td>\nIvacaftor hydrate<\/td>\n1134822-07-3<\/td>\n98.00%<\/td>\nCFTR Potentiator<\/td>\n<\/tr>\n
A3512<\/td>\nIWP-2<\/td>\n686770-61-6<\/td>\n98.00%<\/td>\nWnt production inhibitor,PORCN inhibitor<\/td>\n<\/tr>\n
A3513<\/td>\nIxabepilone<\/td>\n219989-84-1<\/td>\n98.00%<\/td>\nEpothilone B analog;microtubule-stabilizing agent<\/td>\n<\/tr>\n
A3515<\/td>\nJANEX-1<\/td>\n202475-60-3<\/td>\n99.27%<\/td>\nJAK3 inhibitor<\/td>\n<\/tr>\n
A3516<\/td>\nJC-1<\/td>\n3520-43-2<\/td>\n98.00%<\/td>\nProbe for Mitochondrial Membrane Potential<\/td>\n<\/tr>\n
A3517<\/td>\nJDTic<\/td>\n361444-66-8<\/td>\n98.00%<\/td>\nOpioid antagonist<\/td>\n<\/tr>\n
A3518<\/td>\nJDTic 2HCl<\/td>\n785835-79-2<\/td>\n98.00%<\/td>\n\u03ba-opioid receptor antagonist<\/td>\n<\/tr>\n
A3519<\/td>\nJNK-IN-7<\/td>\n1408064-71-0<\/td>\n98.13%<\/td>\nSelective JNK inhibitor<\/td>\n<\/tr>\n
A3520<\/td>\nJNK-IN-8<\/td>\n1410880-22-6<\/td>\n99.45%<\/td>\nJNK inhibitor, selective and irreversible<\/td>\n<\/tr>\n
A3522<\/td>\nKaempferide<\/td>\n491-54-3<\/td>\n99.53%<\/td>\nO-methylated flavonol<\/td>\n<\/tr>\n
A3524<\/td>\nkb NB 142-70<\/td>\n1233533-04-4<\/td>\n98.21%<\/td>\nInhibitor of protein kinase D,selective<\/td>\n<\/tr>\n
A3525<\/td>\nKB-R7943 mesylate<\/td>\n182004-65-5<\/td>\n98.75%<\/td>\nInhibitor of the reverse mode of the Na+\/Ca2+ exchanger<\/td>\n<\/tr>\n
A3526<\/td>\nKetone Ester<\/td>\n1208313-97-6<\/td>\n98.00%<\/td>\nDelaies CNS-OT seizures in rats<\/td>\n<\/tr>\n
A3527<\/td>\nKi20227<\/td>\n623142-96-1<\/td>\n98.43%<\/td>\nC-Fms tyrosine kinase inhibitor<\/td>\n<\/tr>\n
A3528<\/td>\nKinetin<\/td>\n525-79-1<\/td>\n99.89%<\/td>\nPlant growth hormones<\/td>\n<\/tr>\n
A3529<\/td>\nKN-92<\/td>\n176708-42-2<\/td>\n99.55%<\/td>\nCaMKII inhibitor<\/td>\n<\/tr>\n
A3530<\/td>\nKN-92 hydrochloride<\/td>\n1431698-47-3<\/td>\n99.89%<\/td>\nInactive derivative of KN-93,control compound<\/td>\n<\/tr>\n
A3531<\/td>\nKN-92 phosphate<\/td>\n1135280-28-2<\/td>\n99.35%<\/td>\nCaMKII inhibitor<\/td>\n<\/tr>\n
A3532<\/td>\nKN-93<\/td>\n139298-40-1<\/td>\n99.83%<\/td>\nCaMKII inhibitor,selective and cometitive<\/td>\n<\/tr>\n
A3533<\/td>\nKo 143<\/td>\n461054-93-3<\/td>\n98.00%<\/td>\nBCRP inhibitor,potent and selective<\/td>\n<\/tr>\n
A3534<\/td>\nKU14R<\/td>\n189224-48-4<\/td>\n98.00%<\/td>\nI(3)-R antagonist<\/td>\n<\/tr>\n
A3535<\/td>\nKX2-391 dihydrochloride<\/td>\n1038395-65-1<\/td>\n98.00%<\/td>\nSrc kinase inhibitor<\/td>\n<\/tr>\n
A3536<\/td>\nL-165041<\/td>\n79558-09-1<\/td>\n98.30%<\/td>\nPPAR\u03b2\/\u03b4 agonist,cell permeable,potent and selective<\/td>\n<\/tr>\n
A3538<\/td>\nLaropiprant<\/td>\n571170-77-9<\/td>\n98.00%<\/td>\nDP1 receptor antagonist,potent and selective<\/td>\n<\/tr>\n
A3539<\/td>\nLck Inhibitor<\/td>\n847950-09-8<\/td>\n98.00%<\/td>\nLck inhibitor<\/td>\n<\/tr>\n
A3541<\/td>\nLCL161<\/td>\n1005342-46-0<\/td>\n99.81%<\/td>\nAntagonist of IAPs inhibitor<\/td>\n<\/tr>\n
A3542<\/td>\nLCQ-908<\/td>\n956136-95-1<\/td>\n98.00%<\/td>\nDGAT1 inhibitor<\/td>\n<\/tr>\n
A3543<\/td>\nLDE225 Diphosphate<\/td>\n1218778-77-8<\/td>\n99.83%<\/td>\nSmo antagonist<\/td>\n<\/tr>\n
A3544<\/td>\nLDK378 dihydrochloride<\/td>\n1380575-43-8<\/td>\n99.93%<\/td>\nALK inhibitor<\/td>\n<\/tr>\n
A3545<\/td>\nLDN193189 Hydrochloride<\/td>\n1062368-62-0<\/td>\n98.76%<\/td>\nALK inhibitor,potent and selective<\/td>\n<\/tr>\n
A3548<\/td>\nLersivirine<\/td>\n473921-12-9<\/td>\n98.00%<\/td>\nNNRT inhibitor<\/td>\n<\/tr>\n
A3549<\/td>\nLesinurad<\/td>\n878672-00-5<\/td>\n99.77%<\/td>\nURAT1 inhibitor<\/td>\n<\/tr>\n
A3550<\/td>\nLetermovir<\/td>\n917389-32-3<\/td>\n99.52%<\/td>\nNovel anti-CMV compound<\/td>\n<\/tr>\n
A3551<\/td>\nLeuprolide Acetate<\/td>\n74381-53-6<\/td>\n99.74%<\/td>\nPituitary GnRH receptors agonist<\/td>\n<\/tr>\n
A3552<\/td>\nLevomefolate calcium<\/td>\n151533-22-1<\/td>\n99.44%<\/td>\nArtificial form of folate<\/td>\n<\/tr>\n
A3555<\/td>\nLimonin<\/td>\n1180-71-8<\/td>\n99.76%<\/td>\nCarcinogenesis inhibitor and HIV-1 replication inhibitor<\/td>\n<\/tr>\n
A3556<\/td>\nLKB1 (AAK1 dual inhibitor)<\/td>\n1093222-27-5<\/td>\n99.04%<\/td>\nPim-1 kinase inhibitor<\/td>\n<\/tr>\n
A3558<\/td>\nLRRK2-IN-1<\/td>\n1234480-84-2<\/td>\n99.18%<\/td>\nLRRK2 inhibitor,cell-permeable and ATP competitive<\/td>\n<\/tr>\n
A3561<\/td>\nLu AE58054 Hydrochloride<\/td>\n467458-02-2<\/td>\n99.32%<\/td>\n5-HT(6)R antagonist<\/td>\n<\/tr>\n
A3562<\/td>\nLucidin<\/td>\n478-08-0<\/td>\n98.00%<\/td>\nNatural component of Rubia tinctorum L<\/td>\n<\/tr>\n
A3563<\/td>\nLUF6000<\/td>\n890087-21-5<\/td>\n98.00%<\/td>\nA3 AR modulator<\/td>\n<\/tr>\n
A3564<\/td>\nLuliconazole<\/td>\n187164-19-8<\/td>\n99.20%<\/td>\nAzole antifungal agent(interdigital tinea pedis)<\/td>\n<\/tr>\n
A3565<\/td>\nLX-1031<\/td>\n945976-76-1<\/td>\n99.50%<\/td>\nTPH inhibitor<\/td>\n<\/tr>\n
A3566<\/td>\nLX1606<\/td>\n1137608-69-5<\/td>\n98.00%<\/td>\nTryptophan hydroxylase (TPH) inhibitor<\/td>\n<\/tr>\n
A3567<\/td>\nLX-4211<\/td>\n1018899-04-1<\/td>\n99.67%<\/td>\nSGLT1\/SGLT2 inhibitor<\/td>\n<\/tr>\n
A3568<\/td>\nLY 303511<\/td>\n154447-38-8<\/td>\n98.00%<\/td>\nMTOR inhibitor<\/td>\n<\/tr>\n
A3569<\/td>\nLY 344864<\/td>\n186544-26-3<\/td>\n98.00%<\/td>\n5-HT1F receptor agonist,potent and selective<\/td>\n<\/tr>\n
A3570<\/td>\nLY2090314<\/td>\n603288-22-8<\/td>\n99.78%<\/td>\nPotent GSK-3 inhibitor<\/td>\n<\/tr>\n
A3571<\/td>\nLY2183240<\/td>\n874902-19-9<\/td>\n98.00%<\/td>\nBlocker of anandamide uptake,highly potent<\/td>\n<\/tr>\n
A3573<\/td>\nLY2801653<\/td>\n1206799-15-6<\/td>\n99.47%<\/td>\nMET inhibitor<\/td>\n<\/tr>\n
A3575<\/td>\nLY2835219 free base<\/td>\n1231929-97-7<\/td>\n99.42%<\/td>\nCDK inhibitor<\/td>\n<\/tr>\n
A3576<\/td>\nLY2874455<\/td>\n1254473-64-7<\/td>\n98.94%<\/td>\nFGF\/FGFR Inhibitor<\/td>\n<\/tr>\n
A3577<\/td>\nLY341495<\/td>\n201943-63-7<\/td>\n98.00%<\/td>\nMetabotropic glutamate receptor antagonist<\/td>\n<\/tr>\n
A3583<\/td>\nMatrine<\/td>\n519-02-8<\/td>\n98.87%<\/td>\nAlkaloid found in Sophora plant<\/td>\n<\/tr>\n
A3584<\/td>\nMaxacalcitol<\/td>\n103909-75-7<\/td>\n98.00%<\/td>\nNon-calcemic vitamin D3 analog and VDR ligand.<\/td>\n<\/tr>\n
A3586<\/td>\nMB05032<\/td>\n261365-11-1<\/td>\n98.00%<\/td>\nGNG inhibitor,special and efficacious<\/td>\n<\/tr>\n
A3587<\/td>\nMBX-2982<\/td>\n1037792-44-1<\/td>\n98.00%<\/td>\nGPR119 agonist,selective and orally-available<\/td>\n<\/tr>\n
A3588<\/td>\nMC 1046<\/td>\n126860-83-1<\/td>\n98.00%<\/td>\nVitamin D3 analog<\/td>\n<\/tr>\n
A3592<\/td>\nMedetomidine<\/td>\n86347-14-0<\/td>\n98.00%<\/td>\n\u03b12-adrenoceptor agonist<\/td>\n<\/tr>\n
A3593<\/td>\nMefloquine hydrochloride<\/td>\n51773-92-3<\/td>\n99.86%<\/td>\nQuinoline methanol antimalarial agent,<\/td>\n<\/tr>\n
A3594<\/td>\nMEK inhibitor<\/td>\n334951-92-7<\/td>\n98.00%<\/td>\nPotent MEK inhibitor, Antitumor agent<\/td>\n<\/tr>\n
A3599<\/td>\nMetoclopramide<\/td>\n364-62-5<\/td>\n99.94%<\/td>\nDopamine receptor antagonist<\/td>\n<\/tr>\n
A3600<\/td>\nMF63<\/td>\n892549-43-8<\/td>\n98.00%<\/td>\nMPGES-1 inhibitor<\/td>\n<\/tr>\n
A3601<\/td>\nmGlu2 agonist<\/td>\n1311385-32-6<\/td>\n98.00%<\/td>\nAnti-depressants,novel potent agent<\/td>\n<\/tr>\n
A3602<\/td>\nMI-2<\/td>\n1271738-62-5<\/td>\n99.65%<\/td>\nMenin-MLL Inhibitor<\/td>\n<\/tr>\n
A3603<\/td>\nMI-3<\/td>\n1271738-59-0<\/td>\n98.00%<\/td>\nMenin-MLL Inhibitor<\/td>\n<\/tr>\n
A3604<\/td>\nMibefradil<\/td>\n116644-53-2<\/td>\n98.07%<\/td>\nCalcium channel blocker<\/td>\n<\/tr>\n
A3605<\/td>\nMibefradil dihydrochloride<\/td>\n116666-63-8<\/td>\n98.00%<\/td>\nCa2+ channel blocker ,antihypertensive<\/td>\n<\/tr>\n
A3606<\/td>\nMicafungin sodium<\/td>\n208538-73-2<\/td>\n99.56%<\/td>\nInhibitor of \u03b2-(1,3)-D-glucan synthesis;fungicide<\/td>\n<\/tr>\n
A3608<\/td>\nMK 0893<\/td>\n870823-12-4<\/td>\n98.58%<\/td>\nGlucagon receptor\/IGF-1R antagonist<\/td>\n<\/tr>\n
A3609<\/td>\nMK-0591<\/td>\n136668-42-3<\/td>\n98.00%<\/td>\nFLAP inhibitor,potent and selective<\/td>\n<\/tr>\n
A3611<\/td>\nMK-0812<\/td>\n624733-88-6<\/td>\n98.00%<\/td>\nantagonist of chemokine receptor CCR-2<\/td>\n<\/tr>\n
A3612<\/td>\nMK-0974<\/td>\n781649-09-0<\/td>\n98.00%<\/td>\nCGRP receptor antagonist<\/td>\n<\/tr>\n
A3613<\/td>\nMK-2894<\/td>\n1006036-87-8<\/td>\n98.00%<\/td>\nEP4 receptor inhibitor<\/td>\n<\/tr>\n
A3615<\/td>\nMK-3207<\/td>\n957118-49-9<\/td>\n98.00%<\/td>\nCGRP receptor antagonist<\/td>\n<\/tr>\n
A3617<\/td>\nMK-4827<\/td>\n1038915-60-4<\/td>\n98.93%<\/td>\nPARP-1\/-2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3618<\/td>\nMK-5172<\/td>\n1350514-68-9<\/td>\n99.79%<\/td>\nHCV NS3\/4a protease inhibitor<\/td>\n<\/tr>\n
A3619<\/td>\nMK-5172 hydrate<\/td>\n1350462-55-3<\/td>\n98.00%<\/td>\nHCV NS3\/4a protease inhibitor<\/td>\n<\/tr>\n
A3620<\/td>\nMK-5172 potassium salt<\/td>\n1206524-86-8<\/td>\n98.00%<\/td>\nHCV NS3\/4a protease inhibitor<\/td>\n<\/tr>\n
A3621<\/td>\nMK-5172 sodium salt<\/td>\n1425038-27-2<\/td>\n98.00%<\/td>\nHCV NS3\/4a protease inhibitor<\/td>\n<\/tr>\n
A3623<\/td>\nMK-6892<\/td>\n917910-45-3<\/td>\n99.65%<\/td>\nHighly potential GPR109A agonist<\/td>\n<\/tr>\n
A3624<\/td>\nMK-8033<\/td>\n1001917-37-8<\/td>\n98.00%<\/td>\nC-MET inhibitor<\/td>\n<\/tr>\n
A3626<\/td>\nML-7 hydrochloride<\/td>\n110448-33-4<\/td>\n98.43%<\/td>\nMyosin light chain kinase inhibitor<\/td>\n<\/tr>\n
A3627<\/td>\nMLN 2480<\/td>\n1096708-71-2<\/td>\n98.99%<\/td>\nPan-Raf kinase inhibitor,investigational<\/td>\n<\/tr>\n
A3628<\/td>\nMLN120B<\/td>\n783348-36-7<\/td>\n99.82%<\/td>\nI\u03baB Kinase \u03b2 Inhibitor<\/td>\n<\/tr>\n
A3629<\/td>\nMLN4924 HCl salt<\/td>\n1160295-21-5<\/td>\n98.00%<\/td>\nNAE inhibitor<\/td>\n<\/tr>\n
A3630<\/td>\nMMAD<\/td>\n203849-91-6<\/td>\n98.00%<\/td>\nTubulin inhibitor,highly potent<\/td>\n<\/tr>\n
A3631<\/td>\nMonomethyl auristatin E<\/td>\n474645-27-7<\/td>\n98.34%<\/td>\nAntimitotic agent<\/td>\n<\/tr>\n
A3632<\/td>\nMotesanib<\/td>\n453562-69-1<\/td>\n98.00%<\/td>\nInhibitor of Flk-1\/Flt-4\/PDGFR-\/c-Kit<\/td>\n<\/tr>\n
A3633<\/td>\nMPEP Hydrochloride<\/td>\n219911-35-0<\/td>\n98.00%<\/td>\nMGlu5 receptor antagonist<\/td>\n<\/tr>\n
A3634<\/td>\nMPTP hydrochloride<\/td>\n23007-85-4<\/td>\n99.79%<\/td>\nDopaminergic neurotoxin,induced reduction in the DOPAC HVA\/dopamine (DA) ratio<\/td>\n<\/tr>\n
A3636<\/td>\nMTEP hydrochloride<\/td>\n1186195-60-7<\/td>\n98.00%<\/td>\nMGlu5 antagonist<\/td>\n<\/tr>\n
A3637<\/td>\nGDC-mTOR inhibitor<\/td>\n1207358-59-5<\/td>\n98.00%<\/td>\nMTOR inhibitor<\/td>\n<\/tr>\n
A3641<\/td>\nNaphthoquine phosphate<\/td>\n173531-58-3<\/td>\n98.00%<\/td>\nAntimalarial drug<\/td>\n<\/tr>\n
A3642<\/td>\nNarciclasine<\/td>\n29477-83-6<\/td>\n98.00%<\/td>\nModulates the Rho\/ROCK\/LIM kinase\/cofilin pathway<\/td>\n<\/tr>\n
A3643<\/td>\nNarlaprevir<\/td>\n865466-24-6<\/td>\n98.00%<\/td>\nHCV NS3 protease inhibitor<\/td>\n<\/tr>\n
A3645<\/td>\nNB-598<\/td>\n131060-14-5<\/td>\n99.35%<\/td>\nSE inhibitor<\/td>\n<\/tr>\n
A3646<\/td>\nNB-598 hydrochloride<\/td>\n136719-25-0<\/td>\n98.00%<\/td>\nSE inhibitor<\/td>\n<\/tr>\n
A3647<\/td>\nNB-598 Maleate<\/td>\n155294-62-5<\/td>\n98.97%<\/td>\nSqualene epoxidase inhibitor<\/td>\n<\/tr>\n
A3649<\/td>\nNBD-556<\/td>\n333353-44-9<\/td>\n98.00%<\/td>\nHIV-1 entry inhibitor,CD4 mimetic,block gp120-CD4 interaction<\/td>\n<\/tr>\n
A3652<\/td>\nNecrostatin 2<\/td>\n852391-19-6<\/td>\n98.00%<\/td>\nIn vitro necroptosis inhibitor<\/td>\n<\/tr>\n
A3653<\/td>\nNelfinavir Mesylate<\/td>\n159989-65-8<\/td>\n98.04%<\/td>\nHIV protease inhibitor,antiretroviral drug for HIV treatment<\/td>\n<\/tr>\n
A3655<\/td>\nNesbuvir<\/td>\n691852-58-1<\/td>\n99.79%<\/td>\nNS5B polymerase inhibitor<\/td>\n<\/tr>\n
A3658<\/td>\nNG25<\/td>\n1315355-93-1<\/td>\n98.00%<\/td>\nTAK1 inhibitor<\/td>\n<\/tr>\n
A3659<\/td>\nNifuratel<\/td>\n4936-47-4<\/td>\n98.00%<\/td>\nAntibacterial, antifungal, and antiprotozoal compound<\/td>\n<\/tr>\n
A3660<\/td>\nNilotinib monohydrochloride monohydrate<\/td>\n923288-90-8<\/td>\n99.89%<\/td>\nBcr-Abl inhibitor<\/td>\n<\/tr>\n
A3662<\/td>\nNNC 55-0396<\/td>\n357400-13-6<\/td>\n98.00%<\/td>\nT-type calcium channel blocker<\/td>\n<\/tr>\n
A3663<\/td>\nNoopept<\/td>\n157115-85-0<\/td>\n98.00%<\/td>\nNootropic and neuroprotective agent<\/td>\n<\/tr>\n
A3664<\/td>\nNordihydroguaiaretic acid<\/td>\n500-38-9<\/td>\n99.83%<\/td>\nAnti-tumor agent;lipoxygenase inhibitor<\/td>\n<\/tr>\n
A3665<\/td>\nNortadalafil<\/td>\n171596-36-4<\/td>\n98.00%<\/td>\nPDE5 inhibitor<\/td>\n<\/tr>\n
A3666<\/td>\nNP118809<\/td>\n41332-24-5<\/td>\n98.00%<\/td>\nN-type calcium channel blocker<\/td>\n<\/tr>\n
A3667<\/td>\nNPS-2143 hydrochloride<\/td>\n324523-20-8<\/td>\n99.89%<\/td>\nCalcium ion-sensing receptor antagonist<\/td>\n<\/tr>\n
A3668<\/td>\nNS309<\/td>\n18711-16-5<\/td>\n98.00%<\/td>\nCalcium-Activated Potassium Channel activator<\/td>\n<\/tr>\n
A3670<\/td>\nNucleozin<\/td>\n341001-38-5<\/td>\n99.55%<\/td>\nTargets influenza A nucleoprotein (NP),cell-permeable isoxazolylpiperazine compound<\/td>\n<\/tr>\n
A3671<\/td>\nNutlin-3a chiral<\/td>\n675576-98-4<\/td>\n98.39%<\/td>\nMDM2 inhibitor, antiproliferative and antiproapoptotic<\/td>\n<\/tr>\n
A3672<\/td>\nNVP-BAG956<\/td>\n853910-02-8<\/td>\n98.00%<\/td>\nPI3K and PDK1 inhibitor<\/td>\n<\/tr>\n
A3673<\/td>\nNVP-BGJ398 phosphate<\/td>\n1310746-10-1<\/td>\n99.78%<\/td>\nFGFR inhibitor<\/td>\n<\/tr>\n
A3674<\/td>\nNVP-BKM120 Hydrochloride<\/td>\n1312445-63-8<\/td>\n98.02%<\/td>\nPI3K inhibitor<\/td>\n<\/tr>\n
A3675<\/td>\nNVP-BSK805<\/td>\n1092499-93-8<\/td>\n98.00%<\/td>\nATP-competitive JAK2 inhibitor<\/td>\n<\/tr>\n
A3676<\/td>\nNVP-LCQ195<\/td>\n902156-99-4<\/td>\n97.50%<\/td>\nCDK1\/CDK2\/CDK5 inhibitor<\/td>\n<\/tr>\n
A3680<\/td>\nOlcegepant<\/td>\n204697-65-4<\/td>\n97.46%<\/td>\nNon-peptide receptor of CGRP,first potent and selective<\/td>\n<\/tr>\n
A3681<\/td>\nOlmesartan<\/td>\n144689-24-7<\/td>\n99.20%<\/td>\nAngiotensin II receptor antagonist<\/td>\n<\/tr>\n
A3683<\/td>\nOlprinone Hydrochloride<\/td>\n119615-63-3<\/td>\n99.74%<\/td>\nPhosphodiesterase 3 (PDE3) inhibitor, selective<\/td>\n<\/tr>\n
A3684<\/td>\nONO-AE3-208<\/td>\n402473-54-5<\/td>\n97.73%<\/td>\nEP4 receptor antagonist,high affinity and selective<\/td>\n<\/tr>\n
A3686<\/td>\nOrteronel<\/td>\n566939-85-3<\/td>\n98.00%<\/td>\nFor castration-resistant prostate cancer, clinical candidate<\/td>\n<\/tr>\n
A3688<\/td>\nOseltamivir<\/td>\n196618-13-0<\/td>\n96.83%<\/td>\ninhibitor of influenza neuraminidase<\/td>\n<\/tr>\n
A3689<\/td>\nOseltamivir acid<\/td>\n187227-45-8<\/td>\n99.08%<\/td>\nInfluenza neuraminidase inhibitor<\/td>\n<\/tr>\n
A3690<\/td>\nOtamixaban<\/td>\n193153-04-7<\/td>\n98.00%<\/td>\nDirect factor Xa inhibitors,potent and selective<\/td>\n<\/tr>\n
A3691<\/td>\nOtenabant<\/td>\n686344-29-6<\/td>\n98.00%<\/td>\nCB1 receptor antagonist<\/td>\n<\/tr>\n
A3692<\/td>\nOTX-015<\/td>\n202590-98-5<\/td>\n99.57%<\/td>\nBRD inhibitor<\/td>\n<\/tr>\n
A3695<\/td>\nPafuramidine<\/td>\n186953-56-0<\/td>\n98.00%<\/td>\nProdrug of furamidine<\/td>\n<\/tr>\n
A3696<\/td>\nPalifosfamide<\/td>\n31645-39-3<\/td>\n98.00%<\/td>\nActive metabolite of ifosfamide (IFOS)<\/td>\n<\/tr>\n
A3697<\/td>\nPalonosetron<\/td>\n135729-61-2<\/td>\n98.00%<\/td>\n5-HT3 antagonist<\/td>\n<\/tr>\n
A3700<\/td>\nParadol<\/td>\n27113-22-0<\/td>\n98.00%<\/td>\nActive flavor constituent of the seeds of Guinea pepper<\/td>\n<\/tr>\n
A3702<\/td>\nParicalcitol<\/td>\n131918-61-1<\/td>\n98.00%<\/td>\nAnalog of VD2 active form<\/td>\n<\/tr>\n
A3704<\/td>\nPD 123319 ditrifluoroacetate<\/td>\n136676-91-0<\/td>\n99.14%<\/td>\nAngiotensin AT2 receptor antagonist<\/td>\n<\/tr>\n
A3706<\/td>\nPDK1 inhibitor<\/td>\n1001409-50-2<\/td>\n98.00%<\/td>\nPDK1 inhibitor<\/td>\n<\/tr>\n
A3707<\/td>\nPemetrexed disodium hemipenta hydrate<\/td>\n357166-30-4<\/td>\n99.94%<\/td>\nAntifolate and antimetabolite agent<\/td>\n<\/tr>\n
A3708<\/td>\nPentostatin<\/td>\n53910-25-1<\/td>\n99.05%<\/td>\nIrreversible adenosine deaminase inhibitor<\/td>\n<\/tr>\n
A3709<\/td>\nPeramivir<\/td>\n330600-85-6<\/td>\n99.01%<\/td>\nAeuraminidase inhibitor;antiviral drug<\/td>\n<\/tr>\n
A3711<\/td>\nPF-03084014<\/td>\n865773-15-5<\/td>\n98.52%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
A3712<\/td>\nPF-04217903 methanesulfonate<\/td>\n956906-93-7<\/td>\n98.00%<\/td>\nC-Met inhibitor,selective and ATP-competitive<\/td>\n<\/tr>\n
A3715<\/td>\nPF-04971729<\/td>\n1210344-57-2<\/td>\n98.00%<\/td>\nSGLT inhibitor<\/td>\n<\/tr>\n
A3716<\/td>\nPF-3758309<\/td>\n898044-15-0<\/td>\n98.39%<\/td>\nPAK4 inhibitor<\/td>\n<\/tr>\n
A3717<\/td>\nPF-543<\/td>\n1415562-82-1<\/td>\n99.32%<\/td>\nSphK1 inhibitor,cell-permeate,potent and selective<\/td>\n<\/tr>\n
A3718<\/td>\nPF-543 Citrate<\/td>\n1415562-83-2<\/td>\n98.95%<\/td>\nSphK1 inhibitor,potent and cell-permeate<\/td>\n<\/tr>\n
A3719<\/td>\nPF-670462<\/td>\n950912-80-8<\/td>\n99.66%<\/td>\nCK1 \u03b5\/\u03b4 inhibitor<\/td>\n<\/tr>\n
A3720<\/td>\nPF-8380<\/td>\n1144035-53-9<\/td>\n98.23%<\/td>\nAutotaxin inhibitor,potent and specific<\/td>\n<\/tr>\n
A3721<\/td>\nPHA-767491<\/td>\n845714-00-3<\/td>\n99.03%<\/td>\nCdc7\/cdk9 inhibitor, potent, ATP-competitive<\/td>\n<\/tr>\n
A3722<\/td>\nPhenylpiracetam<\/td>\n77472-70-9<\/td>\n99.21%<\/td>\nNootropic derivative of piracetam<\/td>\n<\/tr>\n
A3723<\/td>\nPhloretin<\/td>\n60-82-2<\/td>\n99.12%<\/td>\nA dihydrochalcone found in apple<\/td>\n<\/tr>\n
A3724<\/td>\nPI-103 Hydrochloride<\/td>\n371935-79-4<\/td>\n98.00%<\/td>\nDNA-PK\/PI 3-kinase\/mTOR inhibitor<\/td>\n<\/tr>\n
A3727<\/td>\nPitolisant hydrochloride<\/td>\n903576-44-3<\/td>\n99.71%<\/td>\nNonimidazole inverse agonist<\/td>\n<\/tr>\n
A3729<\/td>\nPJ34<\/td>\n344458-19-1<\/td>\n95.69%<\/td>\nPARP-l inhibitor<\/td>\n<\/tr>\n
A3730<\/td>\nPND-1186<\/td>\n1061353-68-1<\/td>\n99.75%<\/td>\nPotent FAK inhibitor<\/td>\n<\/tr>\n
A3732<\/td>\nPoloxin<\/td>\n321688-88-4<\/td>\n98.00%<\/td>\nPLK1 inhibitor<\/td>\n<\/tr>\n
A3733<\/td>\nPramipexole dihydrochloride<\/td>\n104632-25-9<\/td>\n98.94%<\/td>\nDopamine receptor agonist<\/td>\n<\/tr>\n
A3735<\/td>\nPreladenant<\/td>\n377727-87-2<\/td>\n98.00%<\/td>\nAdenosine A2A receptor antagonist<\/td>\n<\/tr>\n
A3736<\/td>\nPRT062607 Hydrochloride<\/td>\n1370261-97-4<\/td>\n98.63%<\/td>\nSYK inhibitor,potent and selective<\/td>\n<\/tr>\n
A3738<\/td>\nPSI-7977<\/td>\n1190307-88-0<\/td>\n99.81%<\/td>\nAntiviral agents for chronic HCV infection<\/td>\n<\/tr>\n
A3740<\/td>\nPuromycin aminonucleoside<\/td>\n58-60-6<\/td>\n98.19%<\/td>\nAminonucleoside portion of the antibiotic puromycin<\/td>\n<\/tr>\n
A3741<\/td>\nPyridone 6<\/td>\n457081-03-7<\/td>\n99.60%<\/td>\nPan-JAK inhibitor<\/td>\n<\/tr>\n
A3742<\/td>\nPyridostatin<\/td>\n1085412-37-8<\/td>\n98.02%<\/td>\nDrug used for promoting growth arrest<\/td>\n<\/tr>\n
A3744<\/td>\nQuetiapine<\/td>\n111974-69-7<\/td>\n98.00%<\/td>\nDopamine receptor antagonist<\/td>\n<\/tr>\n
A3746<\/td>\nR1530<\/td>\n882531-87-5<\/td>\n98.00%<\/td>\nAntiangiogenesis,mitosis-angiogenesis inhibitor (MAI)<\/td>\n<\/tr>\n
A3747<\/td>\nR-7128<\/td>\n940908-79-2<\/td>\n98.00%<\/td>\nNS5B inhibitor<\/td>\n<\/tr>\n
A3749<\/td>\nRadezolid<\/td>\n869884-78-6<\/td>\n99.32%<\/td>\nNovel oxazolidinone antibiotic agent<\/td>\n<\/tr>\n
A3750<\/td>\nRegorafenib hydrochloride<\/td>\n835621-07-3<\/td>\n98.57%<\/td>\nTyrosine kinase inhibitor<\/td>\n<\/tr>\n
A3752<\/td>\nReparixin<\/td>\n266359-83-5<\/td>\n98.11%<\/td>\nInhibitor of CXCL8 receptor and CXCR1\/CXCR2 activation<\/td>\n<\/tr>\n
A3753<\/td>\nReparixin L-lysine salt<\/td>\n266359-93-7<\/td>\n97.82%<\/td>\nCXCR1\/CXCR2 inhibitor<\/td>\n<\/tr>\n
A3754<\/td>\nRepSox<\/td>\n446859-33-2<\/td>\n99.83%<\/td>\nALK5 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3755<\/td>\nResminostat hydrochloride<\/td>\n1187075-34-8<\/td>\n98.00%<\/td>\nHDAC inhibitor<\/td>\n<\/tr>\n
A3756<\/td>\nRetaspimycin<\/td>\n857402-23-4<\/td>\n98.00%<\/td>\nHSP90 inhibitor,antiproliferative and antineoplastic<\/td>\n<\/tr>\n
A3758<\/td>\nRetigabine dihydrochloride<\/td>\n150812-13-8<\/td>\n99.27%<\/td>\nAntiepileptic compound<\/td>\n<\/tr>\n
A3759<\/td>\nRetinyl glucoside<\/td>\n136778-12-6<\/td>\n98.00%<\/td>\nMetabolites of vitamin A<\/td>\n<\/tr>\n
A3760<\/td>\nReversine<\/td>\n656820-32-5<\/td>\n99.09%<\/td>\nA3 adenosine receptor antagonist,ARK-1\/-2\/-3 inhibitor<\/td>\n<\/tr>\n
A3761<\/td>\nRG2833<\/td>\n1215493-56-3<\/td>\n98.06%<\/td>\nBrain-penetrant HDAC inhibitor<\/td>\n<\/tr>\n
A3762<\/td>\nRG7112<\/td>\n939981-39-2<\/td>\n98.58%<\/td>\nMDM2 inhibitor, first clinical<\/td>\n<\/tr>\n
A3763<\/td>\nRG7388<\/td>\n1229705-06-9<\/td>\n99.82%<\/td>\nMDM2 antagonist, oral, selective<\/td>\n<\/tr>\n
A3764<\/td>\nRI-1<\/td>\n415713-60-9<\/td>\n99.54%<\/td>\nRAD51 inhibitor,cell-permeable<\/td>\n<\/tr>\n
A3765<\/td>\nRilpivirine<\/td>\n500287-72-9<\/td>\n99.64%<\/td>\nInhibitor of next-generation nonnucleoside reverse transcriptase<\/td>\n<\/tr>\n
A3766<\/td>\nRimonabant hydrochloride<\/td>\n158681-13-1<\/td>\n98.01%<\/td>\nCB1 receptor inverse agonist<\/td>\n<\/tr>\n
A3767<\/td>\nRiociguat<\/td>\n625115-55-1<\/td>\n99.77%<\/td>\nSoluble guanylate cyclase (sGC) stimulator<\/td>\n<\/tr>\n
A3768<\/td>\nRivastigmine<\/td>\n123441-03-2<\/td>\n99.68%<\/td>\nCholinesterase inhibitor<\/td>\n<\/tr>\n
A3770<\/td>\nRJR-2403 oxalate<\/td>\n220662-95-3<\/td>\n98.00%<\/td>\nNicotinic receptor agonist<\/td>\n<\/tr>\n
A3771<\/td>\nRKI-1447<\/td>\n1342278-01-6<\/td>\n99.52%<\/td>\nPotent ROCK1\/ROCK2 inhibitor<\/td>\n<\/tr>\n
A3776<\/td>\nRotigotine<\/td>\n99755-59-6<\/td>\n98.00%<\/td>\nAgonist of dopamine D2\/D3 receptor<\/td>\n<\/tr>\n
A3777<\/td>\nRotigotine hydrochloride<\/td>\n125572-93-2<\/td>\n98.00%<\/td>\nAgonist of dopamine D2\/D3 receptor<\/td>\n<\/tr>\n
A3778<\/td>\nRS 127445<\/td>\n199864-87-4<\/td>\n98.01%<\/td>\n5-HT2B receptor antagonist,high affinity<\/td>\n<\/tr>\n
A3780<\/td>\nRU 58841<\/td>\n154992-24-2<\/td>\n98.40%<\/td>\nAndrogen receptor antagonist<\/td>\n<\/tr>\n
A3781<\/td>\nRuxolitinib phosphate<\/td>\n1092939-17-7<\/td>\n98.75%<\/td>\nJAK1\/JAK2 inhibitor<\/td>\n<\/tr>\n
A3783<\/td>\nS0859<\/td>\n1019331-10-2<\/td>\n98.00%<\/td>\nNBC inhibitor,potent and selective<\/td>\n<\/tr>\n
A3784<\/td>\nSafinamide<\/td>\n133865-89-1<\/td>\n99.64%<\/td>\nMAO-B inhibitor<\/td>\n<\/tr>\n
A3787<\/td>\nSalirasib<\/td>\n162520-00-5<\/td>\n99.28%<\/td>\nInhibitor of active Ras protein<\/td>\n<\/tr>\n
A3789<\/td>\nSalmeterol xinafoate<\/td>\n94749-08-3<\/td>\n98.11%<\/td>\n\u03b22-adrenergic receptor agonist<\/td>\n<\/tr>\n
A3790<\/td>\nSaquinavir<\/td>\n127779-20-8<\/td>\n98.00%<\/td>\nHIV Protease Inhibitor<\/td>\n<\/tr>\n
A3791<\/td>\nSaquinavir mesylate<\/td>\n149845-06-7<\/td>\n99.75%<\/td>\nHIV Protease Inhibitor<\/td>\n<\/tr>\n
A3792<\/td>\nSB 239063<\/td>\n193551-21-2<\/td>\n98.63%<\/td>\nP38 MAP kinase inhibitor<\/td>\n<\/tr>\n
A3794<\/td>\nSB1317<\/td>\n937270-47-8<\/td>\n98.02%<\/td>\nCDK,JAK and FLT inhibitor<\/td>\n<\/tr>\n
A3795<\/td>\nSB-222200<\/td>\n174635-69-9<\/td>\n98.86%<\/td>\nHuman NK-3 receptor antagonist<\/td>\n<\/tr>\n
A3798<\/td>\nSB-408124 Hydrochloride<\/td>\n1431697-90-3<\/td>\n98.00%<\/td>\nOX1 receptor antagonist,selective and non-peptide<\/td>\n<\/tr>\n
A3800<\/td>\nSB-674042<\/td>\n483313-22-0<\/td>\n98.00%<\/td>\nOX1 selective antagonist<\/td>\n<\/tr>\n
A3802<\/td>\nSCH 527123<\/td>\n473727-83-2<\/td>\n99.40%<\/td>\nCXCR1 and CXCR2 receptors antagonist<\/td>\n<\/tr>\n
A3804<\/td>\nSCH-1473759<\/td>\n1094069-99-4<\/td>\n98.00%<\/td>\nAurora A\/B inhibitor<\/td>\n<\/tr>\n
A3805<\/td>\nSCH772984<\/td>\n942183-80-4<\/td>\n98.06%<\/td>\nERK1 and ERK2 inhibitor<\/td>\n<\/tr>\n
A3806<\/td>\nSCH900776 S-isomer<\/td>\n891494-64-7<\/td>\n99.18%<\/td>\nCheckpoint kinase(Chk)inhibitor<\/td>\n<\/tr>\n
A3808<\/td>\nSD-208<\/td>\n627536-09-8<\/td>\n99.11%<\/td>\nTGF-\u03b2R I kinase inhibitor<\/td>\n<\/tr>\n
A3809<\/td>\nSDZ 220-581<\/td>\n174575-17-8<\/td>\n98.00%<\/td>\nNMDA glutamate receptor subtype antagonist<\/td>\n<\/tr>\n
A3811<\/td>\nSEA0400<\/td>\n223104-29-8<\/td>\n99.20%<\/td>\nSpecific inhibitor of Na+\/Ca2+ exchange<\/td>\n<\/tr>\n
A3814<\/td>\nSeocalcitol<\/td>\n134404-52-7<\/td>\n98.00%<\/td>\nVitamin D receptor agonist<\/td>\n<\/tr>\n
A3815<\/td>\nSetiptiline<\/td>\n57262-94-9<\/td>\n98.00%<\/td>\nSerotonin receptor antagonist<\/td>\n<\/tr>\n
A3816<\/td>\nSetiptiline maleate<\/td>\n85650-57-3<\/td>\n98.00%<\/td>\nSerotonin receptor antagonist<\/td>\n<\/tr>\n
A3818<\/td>\nSilvestrol<\/td>\n697235-38-4<\/td>\n98.00%<\/td>\nAntineoplastic<\/td>\n<\/tr>\n
A3820<\/td>\nSimeprevir<\/td>\n923604-59-5<\/td>\n99.42%<\/td>\nInhibitor of HCV NS3\/4A protease<\/td>\n<\/tr>\n
A3821<\/td>\nSRT2104 (GSK2245840)<\/td>\n1093403-33-8<\/td>\n98.50%<\/td>\nSIRT1 activator,selective<\/td>\n<\/tr>\n
A3823<\/td>\nSJB2-043<\/td>\n63388-44-3<\/td>\n99.78%<\/td>\nUSP1 inhibitor<\/td>\n<\/tr>\n
A3824<\/td>\nSkepinone-L<\/td>\n1221485-83-1<\/td>\n99.88%<\/td>\nP38-MAPK inhibitor,potent and selective<\/td>\n<\/tr>\n
A3825<\/td>\nSLx-2119<\/td>\n911417-87-3<\/td>\n98.80%<\/td>\nSelective ROCK2 inhibitor<\/td>\n<\/tr>\n
A3826<\/td>\nSMIP004<\/td>\n143360-00-3<\/td>\n98.17%<\/td>\nApoptosis inducer<\/td>\n<\/tr>\n
A3828<\/td>\nSobetirome<\/td>\n211110-63-3<\/td>\n99.01%<\/td>\nAgonist of tyroid hormone receptor<\/td>\n<\/tr>\n
A3829<\/td>\nsodium 4-pentynoate<\/td>\n101917-30-0<\/td>\n98.00%<\/td>\nchemical reporter for the profiling of acetylated proteins<\/td>\n<\/tr>\n
A3832<\/td>\nSolasodine<\/td>\n126-17-0<\/td>\n98.00%<\/td>\nNeuroprotective antioxidant glycoalkaloid<\/td>\n<\/tr>\n
A3834<\/td>\nSQ109<\/td>\n502487-67-4<\/td>\n98.00%<\/td>\nAntibiotic for treatment of pulmonary TB<\/td>\n<\/tr>\n
A3835<\/td>\nSR1078<\/td>\n1246525-60-9<\/td>\n98.65%<\/td>\nOrphan receptor agonist<\/td>\n<\/tr>\n
A3836<\/td>\nSR3335<\/td>\n293753-05-6<\/td>\n99.52%<\/td>\nROR\u03b1 agonist,partial inverse and selective<\/td>\n<\/tr>\n
A3837<\/td>\nDL-\u03b1-Hydroxyglutaric acid disodium salt<\/td>\n40951-21-1<\/td>\n98.00%<\/td>\nalpha hydroxy acid<\/td>\n<\/tr>\n
A3838<\/td>\nSRT3109<\/td>\n1204707-71-0<\/td>\n98.00%<\/td>\nCXCR2 ligand<\/td>\n<\/tr>\n
A3839<\/td>\nSRT3190<\/td>\n1204707-73-2<\/td>\n99.56%<\/td>\nCXCR2 ligand,SIRT1 activator<\/td>\n<\/tr>\n
A3840<\/td>\nST 2825<\/td>\n894787-30-5<\/td>\n98.00%<\/td>\nInhibitor of MyD88 dimerization<\/td>\n<\/tr>\n
A3843<\/td>\nSU 5402<\/td>\n215543-92-3<\/td>\n98.48%<\/td>\nVEGFR2\/FGFR\/PDGFR\/EGFR inhibitor<\/td>\n<\/tr>\n
A3844<\/td>\nSU14813<\/td>\n627908-92-3<\/td>\n98.00%<\/td>\nTyrosine kinase inhibitor<\/td>\n<\/tr>\n
A3846<\/td>\nSU14813 maleate<\/td>\n849643-15-8<\/td>\n98.00%<\/td>\nVEGFR\/PDGFR\/Kit\/FLT-3 inhibitor<\/td>\n<\/tr>\n
A3847<\/td>\nSU5416<\/td>\n204005-46-9<\/td>\n99.06%<\/td>\nVEGF receptor inhibitor and AHR agonist<\/td>\n<\/tr>\n
A3848<\/td>\nTacalcitol<\/td>\n57333-96-7<\/td>\n98.00%<\/td>\nPromotes normal bone development by regulating calcium<\/td>\n<\/tr>\n
A3850<\/td>\nTAK-242<\/td>\n243984-11-4<\/td>\n99.53%<\/td>\nTLR 4 signaling inhibitor<\/td>\n<\/tr>\n
A3853<\/td>\nTalarozole<\/td>\n201410-53-9<\/td>\n98.00%<\/td>\nCytochrome P450 inhibitor<\/td>\n<\/tr>\n
A3854<\/td>\nTalnetant<\/td>\n174636-32-9<\/td>\n98.00%<\/td>\nNK3 receptor antagonist,potent and selective<\/td>\n<\/tr>\n
A3856<\/td>\nTamibarotene<\/td>\n94497-51-5<\/td>\n98.41%<\/td>\nRAR\u03b1 agonist<\/td>\n<\/tr>\n
A3857<\/td>\nTanaproget<\/td>\n304853-42-7<\/td>\n98.00%<\/td>\nProgesterone receptor agonist<\/td>\n<\/tr>\n
A3858<\/td>\nTaranabant<\/td>\n701977-09-5<\/td>\n98.00%<\/td>\nCannabinoid receptor type 1 inverse agonist<\/td>\n<\/tr>\n
A3859<\/td>\nTariquidar methanesulfonate, hydrate<\/td>\n625375-83-9<\/td>\n99.49%<\/td>\nP-glycoprotein inhibitor, potent and selective<\/td>\n<\/tr>\n
A3860<\/td>\nTasquinimod<\/td>\n254964-60-8<\/td>\n99.47%<\/td>\nAntiangiogenic and antineoplastic agent<\/td>\n<\/tr>\n
A3861<\/td>\nTBB<\/td>\n17374-26-4<\/td>\n99.23%<\/td>\nCasein kinase-2 (CK2) inhibitor<\/td>\n<\/tr>\n
A3862<\/td>\nTC-DAPK 6<\/td>\n315694-89-4<\/td>\n98.00%<\/td>\nDAPK inhibitor<\/td>\n<\/tr>\n
A3863<\/td>\nTedizolid<\/td>\n856866-72-3<\/td>\n99.63%<\/td>\nOxazolidinone for gram-positive infections<\/td>\n<\/tr>\n
A3864<\/td>\nTegobuvir<\/td>\n1000787-75-6<\/td>\n98.97%<\/td>\nHCV RNA replication inhibitor<\/td>\n<\/tr>\n
A3865<\/td>\nTeneligliptin hydrobromide<\/td>\n906093-29-6<\/td>\n99.90%<\/td>\nDipeptidyl peptidase-4 inhibitor<\/td>\n<\/tr>\n
A3870<\/td>\nTG 100801<\/td>\n867331-82-6<\/td>\n98.00%<\/td>\nMulti-kinase inhibitor<\/td>\n<\/tr>\n
A3872<\/td>\nTH-302<\/td>\n918633-87-1<\/td>\n98.40%<\/td>\nHypoxia-activated prodrug,inhibits H460\/HT29 cell growth<\/td>\n<\/tr>\n
A3873<\/td>\nTianeptine<\/td>\n66981-73-5; 72797-41-2<\/td>\n99.46%<\/td>\n5-HT facilitator<\/td>\n<\/tr>\n
A3874<\/td>\nTiotropium Bromide<\/td>\n136310-93-5<\/td>\n99.39%<\/td>\nMAChR M antagonist<\/td>\n<\/tr>\n
A3875<\/td>\nTipiracil hydrochloride<\/td>\n183204-72-0<\/td>\n99.74%<\/td>\nThymidine phosphorylase inhibitor<\/td>\n<\/tr>\n
A3876<\/td>\nTipranavir<\/td>\n174484-41-4<\/td>\n98.00%<\/td>\nHIV protease inhibitor<\/td>\n<\/tr>\n
A3877<\/td>\nTirofiban hydrochloride monohydrate<\/td>\n150915-40-5<\/td>\n99.46%<\/td>\nGlycoprotein IIb\/IIIa inhibitor<\/td>\n<\/tr>\n
A3878<\/td>\nTMC353121<\/td>\n857066-90-1<\/td>\n98.00%<\/td>\nPotent RSV fusion inhibitor<\/td>\n<\/tr>\n
A3879<\/td>\nToceranib<\/td>\n356068-94-5<\/td>\n98.00%<\/td>\nc-Kit\/VEGFR\/PDGFR inhibtor<\/td>\n<\/tr>\n
A3881<\/td>\nToll-like receptor modulator<\/td>\n926927-42-6<\/td>\n98.00%<\/td>\nTLR antagonist<\/td>\n<\/tr>\n
A3883<\/td>\nTonabersat<\/td>\n175013-84-0<\/td>\n98.00%<\/td>\nGap junction modulator,novel benzopyran compound for Migraine and epilepsy treatment<\/td>\n<\/tr>\n
A3884<\/td>\nToremifene<\/td>\n89778-26-7<\/td>\n98.00%<\/td>\nEstrogen-receptor modulator<\/td>\n<\/tr>\n
A3885<\/td>\nTozadenant<\/td>\n870070-55-6<\/td>\n99.46%<\/td>\nAdenosine 2a receptor antagonist,novel and selective<\/td>\n<\/tr>\n
A3886<\/td>\nTrabectedin<\/td>\n114899-77-3<\/td>\n98.00%<\/td>\nAntitumour agent<\/td>\n<\/tr>\n
A3887<\/td>\nTrametinib DMSO solvate<\/td>\n1187431-43-1<\/td>\n98.64%<\/td>\nAllosteric MEK1\/MEK2 kinase inhibitor<\/td>\n<\/tr>\n
A3888<\/td>\nTrelagliptin<\/td>\n865759-25-7<\/td>\n99.66%<\/td>\nDPP-4 inhibitor,long-acting and selective<\/td>\n<\/tr>\n
A3889<\/td>\nTrelagliptin succinate<\/td>\n1029877-94-8<\/td>\n98.00%<\/td>\nDPP-4 inhibitor<\/td>\n<\/tr>\n
A3891<\/td>\nTriptolide<\/td>\n38748-32-2<\/td>\n99.16%<\/td>\nIL-2\/MMP-3\/MMP7\/MMP19 inhibitor<\/td>\n<\/tr>\n
A3892<\/td>\nTriptonide<\/td>\n38647-11-9<\/td>\n99.15%<\/td>\ndCTP Pyrophosphatase inhibitor<\/td>\n<\/tr>\n
A3893<\/td>\nTroglitazone<\/td>\n97322-87-7<\/td>\n98.99%<\/td>\nSelective PPAR\u03b3 agonist<\/td>\n<\/tr>\n
A3894<\/td>\nTTP 22<\/td>\n329907-28-0<\/td>\n98.33%<\/td>\nCK2 inhibitor<\/td>\n<\/tr>\n
A3895<\/td>\nTUG-770<\/td>\n1402601-82-4<\/td>\n99.46%<\/td>\nFFA1\/GPR40 agonist<\/td>\n<\/tr>\n
A3896<\/td>\nTulathromycin A<\/td>\n217500-96-4<\/td>\n98.00%<\/td>\nTriamilide antimicrobial<\/td>\n<\/tr>\n
A3899<\/td>\nUK-5099<\/td>\n56396-35-1<\/td>\n99.41%<\/td>\nMCTs and MPC inhibitor<\/td>\n<\/tr>\n
A3900<\/td>\nUmeclidinium bromide<\/td>\n869113-09-7<\/td>\n98.74%<\/td>\nMAChR antagonist<\/td>\n<\/tr>\n
A3901<\/td>\nUNC1215<\/td>\n1415800-43-9<\/td>\n98.55%<\/td>\nChemical probe for the methyllysine (Kme)<\/td>\n<\/tr>\n
A3902<\/td>\nVAL-083<\/td>\n23261-20-3<\/td>\n98.00%<\/td>\nBi-functional alkylating agent<\/td>\n<\/tr>\n
A3903<\/td>\nValaciclovir<\/td>\n124832-26-4<\/td>\n98.00%<\/td>\nProdrug of aciclovir for herpes virus treatment<\/td>\n<\/tr>\n
A3905<\/td>\nValspodar<\/td>\n121584-18-7<\/td>\n96.32%<\/td>\nP-glycoprotein inhibitor<\/td>\n<\/tr>\n
A3906<\/td>\nVandetanib hydrochloride<\/td>\n524722-52-9<\/td>\n99.92%<\/td>\nVEGFR\/EGFR inhibitor<\/td>\n<\/tr>\n
A3909<\/td>\nVCH-916<\/td>\n1200133-34-1<\/td>\n98.00%<\/td>\nHCV NS5B polymerase inhibitor<\/td>\n<\/tr>\n
A3915<\/td>\nVernakalant Hydrochloride<\/td>\n748810-28-8<\/td>\n98.00%<\/td>\nIon channel blocker,investigational antiarrhythmic<\/td>\n<\/tr>\n
A3918<\/td>\nVilazodone<\/td>\n163521-12-8<\/td>\n99.06%<\/td>\nCombined SSRI and 5-HT1A receptor partial agonist<\/td>\n<\/tr>\n
A3919<\/td>\nVilazodone Hydrochloride<\/td>\n163521-08-2<\/td>\n98.38%<\/td>\nCombined SSRI and 5-HT1A receptor partial agonist<\/td>\n<\/tr>\n
A3920<\/td>\nVinblastine sulfate<\/td>\n143-67-9<\/td>\n99.06%<\/td>\nAnti-mitotic agent<\/td>\n<\/tr>\n
A3921<\/td>\nVinorelbine ditartrate<\/td>\n125317-39-7<\/td>\n99.06%<\/td>\nAnti-mitotic chemotherapy drug<\/td>\n<\/tr>\n
A3923<\/td>\nVO-Ohpic trihydrate<\/td>\n476310-60-8<\/td>\n98.00%<\/td>\nPTEN inhibitor<\/td>\n<\/tr>\n
A3924<\/td>\nVoreloxin<\/td>\n175414-77-4<\/td>\n98.00%<\/td>\nTopo II inhibitor<\/td>\n<\/tr>\n
A3925<\/td>\nVoreloxin Hydrochloride<\/td>\n175519-16-1<\/td>\n98.00%<\/td>\nAntineoplastic naphthyridine analogue<\/td>\n<\/tr>\n
A3926<\/td>\nVortioxetine<\/td>\n508233-74-7<\/td>\n99.27%<\/td>\n5-HT receptors antagonist<\/td>\n<\/tr>\n
A3927<\/td>\nVS-5584 (SB2343)<\/td>\n1246560-33-7<\/td>\n99.94%<\/td>\nMTOR\/P13K inhibitor,potent and selective<\/td>\n<\/tr>\n
A3931<\/td>\nVX-11e<\/td>\n896720-20-0<\/td>\n98.99%<\/td>\nERK inhibitor<\/td>\n<\/tr>\n
A3932<\/td>\nWAY 316606<\/td>\n915759-45-4<\/td>\n99.64%<\/td>\nsFRP-1 inhibitor<\/td>\n<\/tr>\n
A3933<\/td>\nWAY-100635<\/td>\n162760-96-5<\/td>\n99.64%<\/td>\n5-HT1A receptor antagonist,potent and selective<\/td>\n<\/tr>\n
A3935<\/td>\nWEHI-539<\/td>\n1431866-33-9<\/td>\n99.23%<\/td>\nBcl-xL inhibitor,potent and selective<\/td>\n<\/tr>\n
A3936<\/td>\nWHI-P97<\/td>\n211555-05-4<\/td>\n98.00%<\/td>\nJanus kinase (JAK)-3 inhibitor<\/td>\n<\/tr>\n
A3937<\/td>\nXL019<\/td>\n945755-56-6<\/td>\n97.66%<\/td>\nJAK2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3939<\/td>\nXL228<\/td>\n898280-07-4<\/td>\n99.32%<\/td>\nIGF1R\/AURORA \/FGFR1-3\/ABL\/SRC family kinases inhibitor<\/td>\n<\/tr>\n
A3940<\/td>\nXL388<\/td>\n1251156-08-7<\/td>\n98.00%<\/td>\nMTOR inhibitor,highly potent and selective<\/td>\n<\/tr>\n
A3942<\/td>\nXMD17-109<\/td>\n1435488-37-1<\/td>\n99.71%<\/td>\nERK-5 inhibitor<\/td>\n<\/tr>\n
A3943<\/td>\nXMD8-92<\/td>\n1234480-50-2<\/td>\n98.18%<\/td>\nBMK1\/ERK5 inhibitor<\/td>\n<\/tr>\n
A3944<\/td>\nX-NeuNAc<\/td>\n160369-85-7<\/td>\n99.58%<\/td>\nSubtrate for chromogeneic assay of neuraminidase activity<\/td>\n<\/tr>\n
A3946<\/td>\nYK-4-279<\/td>\n1037184-44-3<\/td>\n99.72%<\/td>\nRNA Helicase A (RHA) inhibitor<\/td>\n<\/tr>\n
A3947<\/td>\nYM-155 hydrochloride<\/td>\n355406-09-6<\/td>\n98.00%<\/td>\nPotent survivin inhibitor<\/td>\n<\/tr>\n
A3950<\/td>\nZardaverine<\/td>\n101975-10-4<\/td>\n98.00%<\/td>\nPDE III and IV inhibitor<\/td>\n<\/tr>\n
A3952<\/td>\nZiprasidone<\/td>\n146939-27-7<\/td>\n97.77%<\/td>\n5-HT (serotonin)\/dopamine receptor antagonist<\/td>\n<\/tr>\n
A3953<\/td>\nZiprasidone hydrochloride monohydrate<\/td>\n138982-67-9<\/td>\n98.30%<\/td>\n5-HT (serotonin)\/dopamine receptor antagonist<\/td>\n<\/tr>\n
A3954<\/td>\nZM323881<\/td>\n193001-14-8<\/td>\n98.00%<\/td>\nVEGFR-2\/KDR inhibitor,potent and selective<\/td>\n<\/tr>\n
A3956<\/td>\nZosuquidar<\/td>\n167354-41-8<\/td>\n98.49%<\/td>\nMDR modulator<\/td>\n<\/tr>\n
A3958<\/td>\nVeliparib dihydrochloride<\/td>\n912445-05-7<\/td>\n98.56%<\/td>\nPARP-1\/PARP-2 inhibitor<\/td>\n<\/tr>\n
A3962<\/td>\nAZD1208<\/td>\n1204144-28-4<\/td>\n99.82%<\/td>\nPIM kinase inhibitor<\/td>\n<\/tr>\n
A3963<\/td>\nA-769662<\/td>\n844499-71-4<\/td>\n97.68%<\/td>\nAMPK activator,potent and reversible<\/td>\n<\/tr>\n
A3965<\/td>\nBI 2536<\/td>\n755038-02-9<\/td>\n98.78%<\/td>\nPlk1 inhibitor,potent and ATP-competitive<\/td>\n<\/tr>\n
A3966<\/td>\nDoxorubicin<\/td>\n23214-92-8<\/td>\n99.31%<\/td>\nTopo II inhibitor,immunosuppresive antineoplastic antibiotic<\/td>\n<\/tr>\n
A3967<\/td>\nLapatinib Ditosylate<\/td>\n388082-77-7<\/td>\n99.94%<\/td>\nEGFR\/HER2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3968<\/td>\nPF-03716556<\/td>\n928774-43-0<\/td>\n98.00%<\/td>\nAcid pump antagonist,potent and selective<\/td>\n<\/tr>\n
A3969<\/td>\nVatalanib<\/td>\n212141-54-3<\/td>\n99.57%<\/td>\nVEGFR-1\/-2 inhibitor,cell-permeable<\/td>\n<\/tr>\n
A4002<\/td>\nIU1<\/td>\n314245-33-5<\/td>\n99.00%<\/td>\nUsp14 inhibitor<\/td>\n<\/tr>\n
A4003<\/td>\nLDN 57444<\/td>\n668467-91-2<\/td>\n99.79%<\/td>\nUCH-L1 inhibitor,reversible competitve<\/td>\n<\/tr>\n
A4004<\/td>\nNSC 632839 hydrochloride<\/td>\n157654-67-6<\/td>\n98.68%<\/td>\nIsopeptidases inhibitor<\/td>\n<\/tr>\n
A4005<\/td>\nRO4929097<\/td>\n847925-91-1<\/td>\n99.40%<\/td>\n\u03b3 secretase inhibitor<\/td>\n<\/tr>\n
A4006<\/td>\nMK-0752<\/td>\n471905-41-6<\/td>\n99.45%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
A4007<\/td>\nMLN9708<\/td>\n1201902-80-8<\/td>\n99.16%<\/td>\nProteasome inhibitor<\/td>\n<\/tr>\n
A4008<\/td>\nMLN2238<\/td>\n1072833-77-2<\/td>\n98.00%<\/td>\n\u03b25 site of the 20S proteasome inhibitor<\/td>\n<\/tr>\n
A4009<\/td>\nCEP-18770<\/td>\n847499-27-8<\/td>\n98.00%<\/td>\nProteasome inhibitor<\/td>\n<\/tr>\n
A4010<\/td>\nSalinosporamide A (NPI-0052, Marizomib)<\/td>\n437742-34-2<\/td>\n\u226595.00%<\/td>\n20S proteasome inhibitor<\/td>\n<\/tr>\n
A4011<\/td>\nONX-0914 (PR-957)<\/td>\n960374-59-8<\/td>\n95.30%<\/td>\nImmunoproteasome inhibitor,potent and selective<\/td>\n<\/tr>\n
A4012<\/td>\nGabexate mesylate<\/td>\n56974-61-9<\/td>\n99.41%<\/td>\nTrypsin-like serine proteinases inhibitor<\/td>\n<\/tr>\n
A4013<\/td>\nAspirin (Acetylsalicylic acid)<\/td>\n50-78-2<\/td>\n98.92%<\/td>\nCyclooxygenase (COX) inhibitor<\/td>\n<\/tr>\n
A4014<\/td>\nArtemether (SM-224)<\/td>\n71963-77-4<\/td>\n98.00%<\/td>\nSemi-synthetic derivative of artemisinin<\/td>\n<\/tr>\n
A4015<\/td>\nDisulfiram<\/td>\n97-77-8<\/td>\n98.00%<\/td>\nDopamine \u03b2-hydroxylase inhibitor<\/td>\n<\/tr>\n
A4016<\/td>\nApoptosis Activator 2<\/td>\n79183-19-0<\/td>\n98.00%<\/td>\nIndoledione caspase activator, cell-permeable<\/td>\n<\/tr>\n
A4018<\/td>\nYO-01027 (Dibenzazepine, DBZ)<\/td>\n209984-56-5<\/td>\n98.30%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
A4019<\/td>\nLY-411575<\/td>\n209984-57-6<\/td>\n98.21%<\/td>\nGamma secretase inhibitor<\/td>\n<\/tr>\n
A4020<\/td>\nLY2811376<\/td>\n1194044-20-6<\/td>\n98.00%<\/td>\nNon-peptidic BACE1 inhibitor<\/td>\n<\/tr>\n
A4022<\/td>\nBMS-708163 (Avagacestat)<\/td>\n1146699-66-2<\/td>\n98.73%<\/td>\n\u03b3-secretase inhibitor<\/td>\n<\/tr>\n
A4023<\/td>\nLY3039478<\/td>\n1421438-81-4<\/td>\n97.16%<\/td>\nNotch inhibitor, novel and potent<\/td>\n<\/tr>\n
A4024<\/td>\nDanoprevir (RG7227)<\/td>\n850876-88-9<\/td>\n98.47%<\/td>\nHCV NS3\/4A protease inhibitor<\/td>\n<\/tr>\n
A4031<\/td>\nTelaprevir (VX-950)<\/td>\n402957-28-2<\/td>\n98.00%<\/td>\nHCV NS3-4A protease inhibitor<\/td>\n<\/tr>\n
A4032<\/td>\nVX-222 (VCH-222, Lomibuvir)<\/td>\n1026785-59-0<\/td>\n99.91%<\/td>\nNNI of HCV RNA polymerase<\/td>\n<\/tr>\n
A4033<\/td>\nGlimepiride<\/td>\n93479-97-1<\/td>\n98.14%<\/td>\nSulfonylurea compound<\/td>\n<\/tr>\n
A4034<\/td>\nLinagliptin (BI-1356)<\/td>\n668270-12-0<\/td>\n99.69%<\/td>\nDDP-4 inhibitor,highly potent and competitive<\/td>\n<\/tr>\n
A4036<\/td>\nSitagliptin phosphate monohydrate<\/td>\n654671-77-9<\/td>\n98.19%<\/td>\nPotent DPP-4 inhibitor<\/td>\n<\/tr>\n
A4037<\/td>\nVildagliptin (LAF-237)<\/td>\n274901-16-5<\/td>\n98.05%<\/td>\nDPP-4 inhibitor<\/td>\n<\/tr>\n
A4038<\/td>\nAlogliptin (SYR-322)<\/td>\n850649-61-5<\/td>\n97.66%<\/td>\nDPP-4 inhibitor,potent and highly selective<\/td>\n<\/tr>\n
A4040<\/td>\nAtazanavir sulfate (BMS-232632-05)<\/td>\n229975-97-7<\/td>\n99.68%<\/td>\nProtease inhibitor<\/td>\n<\/tr>\n
A4049<\/td>\nMarimastat<\/td>\n154039-60-8<\/td>\n98.00%<\/td>\nMMPs inhibitor,board spectrum<\/td>\n<\/tr>\n
A4050<\/td>\nGM 6001<\/td>\n142880-36-2<\/td>\n98.68%<\/td>\nBroad spectrum MMP inhibitor<\/td>\n<\/tr>\n
A4051<\/td>\nNSC 405020<\/td>\n7497-07-6<\/td>\n99.13%<\/td>\nMT1-MMP inhibitor<\/td>\n<\/tr>\n
A4052<\/td>\nDoxycycline hyclate<\/td>\n24390-14-5<\/td>\n98.00%<\/td>\nMMP inhibitor<\/td>\n<\/tr>\n
A4054<\/td>\n17-AAG (KOS953)<\/td>\n75747-14-7<\/td>\n98.53%<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
A4056<\/td>\nAT13387<\/td>\n912999-49-6<\/td>\n99.12%<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
A4057<\/td>\nAUY922 (NVP-AUY922)<\/td>\n747412-49-3<\/td>\n98.26%<\/td>\nPotent Hsp90 inhibitor<\/td>\n<\/tr>\n
A4058<\/td>\nBIIB021<\/td>\n848695-25-0<\/td>\n99.51%<\/td>\nHsp90 inhibitor,selective and competitive<\/td>\n<\/tr>\n
A4060<\/td>\nGeldanamycin<\/td>\n30562-34-6<\/td>\n97.01%<\/td>\nHsp90 inhibitor,potent and specific<\/td>\n<\/tr>\n
A4061<\/td>\nIPI-504 (Retaspimycin hydrochloride)<\/td>\n857402-63-2<\/td>\n98.20%<\/td>\nHsp90 inhibitor,novel, potent,selective<\/td>\n<\/tr>\n
A4062<\/td>\nKW-2478<\/td>\n819812-04-9<\/td>\n98.00%<\/td>\nPotent Hsp90 inhibitor, novel, non-ansamycin,<\/td>\n<\/tr>\n
A4063<\/td>\nMPC-3100<\/td>\n958025-66-6<\/td>\n98.00%<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
A4064<\/td>\nNVP-BEP800<\/td>\n847559-80-2<\/td>\n99.22%<\/td>\nOral Hsp90\u03b2 inhibitor, novel, fully synthetic<\/td>\n<\/tr>\n
A4065<\/td>\nPF-04929113 (SNX-5422)<\/td>\n908115-27-5<\/td>\n99.61%<\/td>\nHsp90 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4067<\/td>\nRadicicol<\/td>\n12772-57-5<\/td>\n98.00%<\/td>\nATPase\/kinase inhibitor<\/td>\n<\/tr>\n
A4068<\/td>\nSNX-2112<\/td>\n908112-43-6<\/td>\n98.00%<\/td>\nHsp90 inhibitor,ATP-competitve,potent and selective<\/td>\n<\/tr>\n
A4069<\/td>\nBMS-707035<\/td>\n729607-74-3<\/td>\n99.68%<\/td>\nHIV-I integrase inhibitor,potent and specific<\/td>\n<\/tr>\n
A4070<\/td>\nElvitegravir (GS-9137)<\/td>\n697761-98-1<\/td>\n99.07%<\/td>\nHIV-1 integrase inhibitor,potent<\/td>\n<\/tr>\n
A4071<\/td>\nFluorouracil (Adrucil)<\/td>\n51-21-8<\/td>\n99.94%<\/td>\nAntitumor agent;inhibitor of thymidylate synthase<\/td>\n<\/tr>\n
A4073<\/td>\nRaltegravir (MK-0518)<\/td>\n518048-05-0<\/td>\n99.73%<\/td>\nHIV-1 integrase inhibitor<\/td>\n<\/tr>\n
A4074<\/td>\nS\/GSK1349572<\/td>\n1051375-16-6<\/td>\n99.89%<\/td>\nHIV integrase inhibitor, novel and potent<\/td>\n<\/tr>\n
A4077<\/td>\nBIBR 953 (Dabigatran, Pradaxa)<\/td>\n211914-51-1<\/td>\n99.44%<\/td>\nThrombin inhibitor,potent,reversible and direct<\/td>\n<\/tr>\n
A4078<\/td>\nCaptopril<\/td>\n62571-86-2<\/td>\n98.91%<\/td>\nACE inhibitor<\/td>\n<\/tr>\n
A4079<\/td>\nFosinopril sodium<\/td>\n88889-14-9<\/td>\n98.00%<\/td>\nACE inhibitor<\/td>\n<\/tr>\n
A4080<\/td>\nMoxonidine<\/td>\n75438-57-2<\/td>\n99.53%<\/td>\nI1R\/\u03b12AR agonist<\/td>\n<\/tr>\n
A4082<\/td>\nOlmesartan medoxomil<\/td>\n144689-63-4<\/td>\n99.38%<\/td>\nAT1 receptor antagonist<\/td>\n<\/tr>\n
A4083<\/td>\nRocilinostat (ACY-1215)<\/td>\n1316214-52-4<\/td>\n99.40%<\/td>\nSelective HDAC6 inhibitor<\/td>\n<\/tr>\n
A4084<\/td>\nVorinostat (SAHA, MK0683)<\/td>\n149647-78-9<\/td>\n99.89%<\/td>\nHDAC inhibitor<\/td>\n<\/tr>\n
A4089<\/td>\nMocetinostat (MGCD0103, MG0103)<\/td>\n726169-73-9<\/td>\n98.49%<\/td>\nHDAC inhibitor,isotype-selective and potent<\/td>\n<\/tr>\n
A4090<\/td>\nJNJ-26481585<\/td>\n875320-29-9<\/td>\n99.01%<\/td>\nPotent HDAC inhibitor<\/td>\n<\/tr>\n
A4091<\/td>\nPCI-34051<\/td>\n950762-95-5<\/td>\n98.67%<\/td>\nHDAC8 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4092<\/td>\nCUDC-101<\/td>\n1012054-59-9<\/td>\n99.56%<\/td>\nMultitargeted HDAC inhibitor<\/td>\n<\/tr>\n
A4093<\/td>\nITF2357 (Givinostat)<\/td>\n732302-99-7<\/td>\n98.28%<\/td>\nHDAC inhibitor<\/td>\n<\/tr>\n
A4094<\/td>\nMC1568<\/td>\n852475-26-4<\/td>\n98.44%<\/td>\nClass II HDAC inhibitor,potent and selective<\/td>\n<\/tr>\n
A4095<\/td>\nPracinostat (SB939)<\/td>\n929016-96-6<\/td>\n98.89%<\/td>\nPan-HDAC inhibitor<\/td>\n<\/tr>\n
A4096<\/td>\nBelinostat (PXD101)<\/td>\n414864-00-9<\/td>\n98.04%<\/td>\nHydroxamate-type HDAC inhibitor<\/td>\n<\/tr>\n
A4097<\/td>\nCUDC-907<\/td>\n1339928-25-4<\/td>\n98.06%<\/td>\nPotent PI3K\/HDAC inhibitor<\/td>\n<\/tr>\n
A4098<\/td>\nPCI-24781 (CRA-024781)<\/td>\n783355-60-2<\/td>\n98.01%<\/td>\nPan-HDAC inhibitor<\/td>\n<\/tr>\n
A4099<\/td>\nValproic acid sodium salt (Sodium valproate)<\/td>\n1069-66-5<\/td>\n98.07%<\/td>\nHDAC inhibitor<\/td>\n<\/tr>\n
A4100<\/td>\nDroxinostat<\/td>\n99873-43-5<\/td>\n98.00%<\/td>\nSelective HDAC inhibitor<\/td>\n<\/tr>\n
A4101<\/td>\nTubastatin A<\/td>\n1252003-15-8<\/td>\n98.00%<\/td>\nHDAC6 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4102<\/td>\nCI994 (Tacedinaline)<\/td>\n112522-64-2<\/td>\n98.17%<\/td>\nHDAC inhibitor<\/td>\n<\/tr>\n
A4103<\/td>\nLAQ824 (NVP-LAQ824,Dacinostat)<\/td>\n404951-53-7<\/td>\n98.12%<\/td>\nHDAC inhibitor,potent and novel<\/td>\n<\/tr>\n
A4104<\/td>\nAR-42 (OSU-HDAC42)<\/td>\n935881-37-1<\/td>\n99.03%<\/td>\nHDAC inhibitor,novel and potent<\/td>\n<\/tr>\n
A4105<\/td>\nM344<\/td>\n251456-60-7<\/td>\n98.73%<\/td>\nHDAC inhibitor,potent and cell-permeable<\/td>\n<\/tr>\n
A4106<\/td>\nScriptaid<\/td>\n287383-59-9<\/td>\n98.70%<\/td>\nHDAC inhibitor,novel and cell-permeable<\/td>\n<\/tr>\n
A4107<\/td>\nSodium Phenylbutyrate<\/td>\n1716-12-7<\/td>\n99.78%<\/td>\nHistone deacetylase inhibitor<\/td>\n<\/tr>\n
A4108<\/td>\nResminostat (RAS2410)<\/td>\n864814-88-0<\/td>\n98.00%<\/td>\nPotent HDAC inhibitor<\/td>\n<\/tr>\n
A4110<\/td>\nMLN8237 (Alisertib)<\/td>\n1028486-01-2<\/td>\n98.77%<\/td>\nAurora A Kinase inhibitor, Potent and selective<\/td>\n<\/tr>\n
A4111<\/td>\nVX-680 (MK-0457,Tozasertib)<\/td>\n639089-54-6<\/td>\n99.93%<\/td>\nAurora kinase inhibitor<\/td>\n<\/tr>\n
A4112<\/td>\nBarasertib (AZD1152-HQPA)<\/td>\n722544-51-6<\/td>\n98.25%<\/td>\nAurora Kinase B inhibitor, Potent and selective<\/td>\n<\/tr>\n
A4113<\/td>\nZM 447439<\/td>\n331771-20-1<\/td>\n98.80%<\/td>\nAurora Kinase inhibitor,potent and selective<\/td>\n<\/tr>\n
A4114<\/td>\nMLN8054<\/td>\n869363-13-3<\/td>\n97.64%<\/td>\nAurora A inhibitor<\/td>\n<\/tr>\n
A4115<\/td>\nJNJ-7706621<\/td>\n443797-96-4<\/td>\n98.11%<\/td>\nPotent CDK\/Aurora kinase inhibitor<\/td>\n<\/tr>\n
A4116<\/td>\nDanusertib (PHA-739358)<\/td>\n827318-97-8<\/td>\n99.39%<\/td>\nPan-aurora kinase inhibitor<\/td>\n<\/tr>\n
A4117<\/td>\nAT9283<\/td>\n896466-04-9<\/td>\n99.29%<\/td>\nAurora kinase\/JAK inhibitor<\/td>\n<\/tr>\n
A4118<\/td>\nHesperadin<\/td>\n422513-13-1<\/td>\n98.29%<\/td>\nAurora B kinase inhibitor<\/td>\n<\/tr>\n
A4119<\/td>\nAMG-900<\/td>\n945595-80-2<\/td>\n98.99%<\/td>\nAurora kinase inhibitor<\/td>\n<\/tr>\n
A4120<\/td>\nMK-5108 (VX-689)<\/td>\n1010085-13-8<\/td>\n96.91%<\/td>\nAurora-A kinase inhibitor,highly selective<\/td>\n<\/tr>\n
A4121<\/td>\nSNS-314 Mesylate<\/td>\n1146618-41-8<\/td>\n99.94%<\/td>\nAurora A\/B\/C kinases inhibitor, potent and selective<\/td>\n<\/tr>\n
A4122<\/td>\nPHA-680632<\/td>\n398493-79-3<\/td>\n98.53%<\/td>\nAurora kinase inhibitor,novel and potent<\/td>\n<\/tr>\n
A4123<\/td>\nKW 2449<\/td>\n1000669-72-6<\/td>\n99.94%<\/td>\nMultikinase inhibitor<\/td>\n<\/tr>\n
A4124<\/td>\nTAK-901<\/td>\n934541-31-8<\/td>\n98.00%<\/td>\nNovel Aurora A\/B inhibitor<\/td>\n<\/tr>\n
A4125<\/td>\nCYC116<\/td>\n693228-63-6<\/td>\n98.71%<\/td>\nPotent Aurora A\/B inhibitor<\/td>\n<\/tr>\n
A4126<\/td>\nAurora A Inhibitor I<\/td>\n1158838-45-9<\/td>\n98.83%<\/td>\nAurora A inhibitor<\/td>\n<\/tr>\n
A4127<\/td>\nGSK1070916<\/td>\n942918-07-2<\/td>\n98.00%<\/td>\nAurora B\/C inhibitor<\/td>\n<\/tr>\n
A4128<\/td>\nPF-03814735<\/td>\n942487-16-3<\/td>\n98.00%<\/td>\nAurora A\/B inhibitor<\/td>\n<\/tr>\n
A4129<\/td>\nENMD-2076 L-(+)-Tartaric acid<\/td>\n1291074-87-7<\/td>\n99.36%<\/td>\nAurora kinases inhibitor<\/td>\n<\/tr>\n
A4130<\/td>\nENMD-2076<\/td>\n934353-76-1<\/td>\n98.78%<\/td>\nSelective Aurora A\/Flt3 inhibitor<\/td>\n<\/tr>\n
A4132<\/td>\nCCT137690<\/td>\n1095382-05-0<\/td>\n98.00%<\/td>\nAurora A\/B\/C inhibitor<\/td>\n<\/tr>\n
A4135<\/td>\nTofacitinib (CP-690550) Citrate<\/td>\n540737-29-9<\/td>\n99.64%<\/td>\nPotent JAK inhibitor<\/td>\n<\/tr>\n
A4136<\/td>\nTG101348 (SAR302503)<\/td>\n936091-26-8<\/td>\n99.39%<\/td>\nJAK-2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4137<\/td>\nAZD1480<\/td>\n935666-88-9<\/td>\n99.31%<\/td>\nJAK2 inhibitor,ATP-competitive and novel<\/td>\n<\/tr>\n
A4138<\/td>\nTofacitinib (CP-690550,Tasocitinib)<\/td>\n477600-75-2<\/td>\n99.94%<\/td>\nJanus kinase inhibitor<\/td>\n<\/tr>\n
A4139<\/td>\nAG-490<\/td>\n133550-30-8<\/td>\n99.76%<\/td>\nJAK2\/EGFR inhibitor<\/td>\n<\/tr>\n
A4140<\/td>\nWP1066<\/td>\n857064-38-1<\/td>\n99.84%<\/td>\nJAK2\/STAT3 inhibitor,cell-permeable<\/td>\n<\/tr>\n
A4141<\/td>\nBaricitinib (LY3009104, INCB028050)<\/td>\n1187594-09-7<\/td>\n98.06%<\/td>\nJAK1\/JAK2 inhibitor,selective orally bioavailable<\/td>\n<\/tr>\n
A4143<\/td>\nCYT387<\/td>\n1056634-68-4<\/td>\n98.70%<\/td>\nJAK-1\/-2 inhibitor,ATP competitive<\/td>\n<\/tr>\n
A4144<\/td>\nAZ 960<\/td>\n905586-69-8<\/td>\n98.00%<\/td>\nJAKs inhibitor<\/td>\n<\/tr>\n
A4145<\/td>\nTG101209<\/td>\n936091-14-4<\/td>\n99.46%<\/td>\nJAK2\/3 inhibitor<\/td>\n<\/tr>\n
A4146<\/td>\nCEP-33779<\/td>\n1257704-57-6<\/td>\n98.00%<\/td>\nJAK2 inhibitor,highly selective<\/td>\n<\/tr>\n
A4147<\/td>\nLY2784544<\/td>\n1229236-86-5<\/td>\n98.00%<\/td>\nJAK2 inhibitor,highly potent and selective<\/td>\n<\/tr>\n
A4148<\/td>\nNVP-BSK805 2HCl<\/td>\n1092499-93-8 (free base)<\/td>\n99.23%<\/td>\nJAK2 inhibitor<\/td>\n<\/tr>\n
A4149<\/td>\nS-Ruxolitinib (INCB018424)<\/td>\n941685-37-6<\/td>\n99.34%<\/td>\nJAK1\/2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4150<\/td>\nWHI-P154<\/td>\n211555-04-3<\/td>\n99.19%<\/td>\nJAK3 inhibitor<\/td>\n<\/tr>\n
A4151<\/td>\nZM 39923 HCl<\/td>\n1021868-92-7<\/td>\n99.91%<\/td>\nJAK3 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4152<\/td>\nBMS-911543<\/td>\n1271022-90-2<\/td>\n98.41%<\/td>\nJAK2 inhibitor,selective small molecule<\/td>\n<\/tr>\n
A4153<\/td>\nBMN 673<\/td>\n1207456-01-6<\/td>\n99.26%<\/td>\nPotent PARP inhibitor<\/td>\n<\/tr>\n
A4154<\/td>\nOlaparib (AZD2281, Ku-0059436)<\/td>\n763113-22-0<\/td>\n99.80%<\/td>\nPotent PARP1\/PARP2 inhibitor<\/td>\n<\/tr>\n
A4156<\/td>\nRucaparib (AG-014699,PF-01367338)<\/td>\n459868-92-9<\/td>\n98.46%<\/td>\nPotent PARP inhibitor<\/td>\n<\/tr>\n
A4157<\/td>\nIniparib (BSI-201)<\/td>\n160003-66-7<\/td>\n99.08%<\/td>\nPARP1 inhibitor,intravenously adminsitered<\/td>\n<\/tr>\n
A4158<\/td>\nAG-14361<\/td>\n328543-09-5<\/td>\n99.17%<\/td>\nPotent PARP1 inhibitor<\/td>\n<\/tr>\n
A4159<\/td>\nPJ34 hydrochloride<\/td>\n344458-15-7<\/td>\n99.54%<\/td>\nPARP inhibitor,potent and cell-permeable<\/td>\n<\/tr>\n
A4160<\/td>\nA-966492<\/td>\n934162-61-5<\/td>\n99.03%<\/td>\nPARP-1\/-2 inhibitor, highly potent<\/td>\n<\/tr>\n
A4161<\/td>\n3-aminobenzamide<\/td>\n3544-24-9<\/td>\n99.66%<\/td>\nPotent PARP inhibitor<\/td>\n<\/tr>\n
A4163<\/td>\nUPF 1069<\/td>\n1048371-03-4<\/td>\n98.00%<\/td>\nSelective PARP2 inhibitor<\/td>\n<\/tr>\n
A4164<\/td>\nAZD2461<\/td>\n1174043-16-3<\/td>\n98.00%<\/td>\nNovel PARP inhibitor<\/td>\n<\/tr>\n
A4166<\/td>\nEPZ5676<\/td>\n1380288-87-8<\/td>\n99.28%<\/td>\nDOT1L inhibitor,potent and SAM competitive<\/td>\n<\/tr>\n
A4167<\/td>\nSGC 0946<\/td>\n1561178-17-3<\/td>\n99.65%<\/td>\nDOT1L inhibitor,highly potent and selective<\/td>\n<\/tr>\n
A4168<\/td>\nEntacapone<\/td>\n130929-57-6<\/td>\n99.28%<\/td>\nCOMT inhibitor<\/td>\n<\/tr>\n
A4170<\/td>\nEPZ004777<\/td>\n1338466-77-5<\/td>\n99.43%<\/td>\nDOT1L inhibitor<\/td>\n<\/tr>\n
A4171<\/td>\nEPZ005687<\/td>\n1396772-26-1<\/td>\n98.66%<\/td>\nEZH2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4176<\/td>\nThioguanine<\/td>\n154-42-7<\/td>\n98.18%<\/td>\nPurine antimetabolite<\/td>\n<\/tr>\n
A4180<\/td>\nSRT1720 HCl<\/td>\n1001645-58-4<\/td>\n99.52%<\/td>\nSIRT1 activator<\/td>\n<\/tr>\n
A4181<\/td>\nEX 527 (SEN0014196)<\/td>\n49843-98-3<\/td>\n99.71%<\/td>\nSIRT1 inhibitor<\/td>\n<\/tr>\n
A4182<\/td>\nResveratrol<\/td>\n501-36-0<\/td>\n99.94%<\/td>\nSIRT1 activator<\/td>\n<\/tr>\n
A4183<\/td>\nSirtinol<\/td>\n410536-97-9<\/td>\n98.00%<\/td>\nSIRT inhibitor<\/td>\n<\/tr>\n
A4184<\/td>\nPFI-1 (PF-6405761)<\/td>\n1403764-72-6<\/td>\n97.20%<\/td>\nBET inhibitor<\/td>\n<\/tr>\n
A4186<\/td>\nBromosporine<\/td>\n1619994-69-2<\/td>\n98.00%<\/td>\nBromodomain inhibitor,non-selective<\/td>\n<\/tr>\n
A4187<\/td>\nFG-4592 (ASP1517)<\/td>\n808118-40-3<\/td>\n99.92%<\/td>\nHIF prolyl-hydroxylase inhibitor<\/td>\n<\/tr>\n
A4188<\/td>\n2-Methoxyestradiol (2-MeOE2)<\/td>\n362-07-2<\/td>\n99.00%<\/td>\nApoptotic, antiproliferative and antiangiogenic agent<\/td>\n<\/tr>\n
A4189<\/td>\nIOX2(Glycine)<\/td>\n931398-72-0<\/td>\n98.10%<\/td>\nHIF-1\u03b1 prolyl hydroxylase-2 (PHD2) inhibitor<\/td>\n<\/tr>\n
A4190<\/td>\nGSK J4 HCl<\/td>\n1373423-53-0(free base)<\/td>\n98.00%<\/td>\nInhibitor of H3K27 demethylase JMJD3,potent and cell-permeable<\/td>\n<\/tr>\n
A4191<\/td>\nGSK J1<\/td>\n1373422-53-7<\/td>\n99.50%<\/td>\nH3K27 demethylase JMJD3 inhibitor<\/td>\n<\/tr>\n
A4192<\/td>\nSGI-1776 free base<\/td>\n1025065-69-3<\/td>\n99.19%<\/td>\nPim kinase inhibitor,ATP-competitive<\/td>\n<\/tr>\n
A4193<\/td>\nSMI-4a<\/td>\n438190-29-5<\/td>\n99.76%<\/td>\nPotent Pim inhibitor<\/td>\n<\/tr>\n
A4194<\/td>\nObatoclax mesylate (GX15-070)<\/td>\n803712-79-0<\/td>\n98.49%<\/td>\nPotent Bcl-2 inhibitor<\/td>\n<\/tr>\n
A4199<\/td>\nSabutoclax<\/td>\n1228108-65-3<\/td>\n98.00%<\/td>\npan-Bcl-2 inhibitor<\/td>\n<\/tr>\n
A4200<\/td>\nApogossypolone (ApoG2)<\/td>\n886578-07-0<\/td>\n98.00%<\/td>\nBcl-2 inhibitor,nonpeptidic small molecule<\/td>\n<\/tr>\n
A4202<\/td>\nRITA (NSC 652287)<\/td>\n213261-59-7<\/td>\n99.53%<\/td>\nMdm2-p53 interaction and p53 ubiquitination blocking<\/td>\n<\/tr>\n
A4203<\/td>\nTenovin-1<\/td>\n380315-80-0<\/td>\n99.90%<\/td>\nSIRT2 inhibitor, activates p53<\/td>\n<\/tr>\n
A4204<\/td>\nJNJ-26854165 (Serdemetan)<\/td>\n881202-45-5<\/td>\n98.35%<\/td>\nP53 activator, blocking Mdm2-p53 interaction<\/td>\n<\/tr>\n
A4206<\/td>\nPifithrin-\u03b1 (PFT\u03b1)<\/td>\n63208-82-2<\/td>\n98.16%<\/td>\np53 inhibitor<\/td>\n<\/tr>\n
A4208<\/td>\nNSC 319726<\/td>\n71555-25-4<\/td>\n98.00%<\/td>\nReactivator of mutant p53<\/td>\n<\/tr>\n
A4209<\/td>\nNSC 207895 (XI-006)<\/td>\n58131-57-0<\/td>\n98.00%<\/td>\nMDMX inhibitor,anti-cancer agent<\/td>\n<\/tr>\n
A4210<\/td>\nBay 11-7821 (BAY 11-7082)<\/td>\n19542-67-7<\/td>\n99.91%<\/td>\nIKK\/NF-\u03baB\/TNF\u03b1 inhibitor<\/td>\n<\/tr>\n
A4211<\/td>\nLenalidomide (CC-5013)<\/td>\n191732-72-6<\/td>\n98.66%<\/td>\nAntineoplastic agent,inhibits angiogenesis<\/td>\n<\/tr>\n
A4212<\/td>\nPomalidomide (CC-4047)<\/td>\n19171-19-8<\/td>\n98.46%<\/td>\nImmunomodulator,antumor\/anti-angiogenic<\/td>\n<\/tr>\n
A4213<\/td>\nNecrostatin-1<\/td>\n4311-88-0<\/td>\n99.88%<\/td>\nRIP1 inhibitor<\/td>\n<\/tr>\n
A4216<\/td>\nThalidomide<\/td>\n50-35-1<\/td>\n99.21%<\/td>\nImmunomodulatory agent,sedative drug,angiogenesis inhibitor<\/td>\n<\/tr>\n
A4217<\/td>\nQNZ (EVP4593)<\/td>\n545380-34-5<\/td>\n99.41%<\/td>\nPotent NF-\u03baB inhibitor<\/td>\n<\/tr>\n
A4219<\/td>\nBirinapant (TL32711)<\/td>\n1260251-31-7<\/td>\n98.13%<\/td>\nPotent XIAP\/cIAP1 antagonist<\/td>\n<\/tr>\n
A4221<\/td>\nYM155<\/td>\n781661-94-7<\/td>\n99.60%<\/td>\nSurvivin suppressant,apoptosis inhibitor<\/td>\n<\/tr>\n
A4224<\/td>\nGDC-0152<\/td>\n873652-48-3<\/td>\n99.00%<\/td>\nIAP antagonist,potent amd samll-molecule<\/td>\n<\/tr>\n
A4227<\/td>\nTipifarnib (Zarnestra)<\/td>\n192185-72-1<\/td>\n99.18%<\/td>\nFarnesyltransferase inhibitor,potent and specific<\/td>\n<\/tr>\n
A4228<\/td>\nNutlin-3<\/td>\n890090-75-2<\/td>\n98.35%<\/td>\nMDM2 antagonist,inhibits MDM2-p53 interaction<\/td>\n<\/tr>\n
A4230<\/td>\nNSC 66811<\/td>\n6964-62-1<\/td>\n98.00%<\/td>\nMDM2 inhibitor<\/td>\n<\/tr>\n
A4232<\/td>\nCyclophosphamide monohydrate<\/td>\n6055-19-2<\/td>\n98.00%<\/td>\nalkylating, cytotoxic agent,antitumor activity<\/td>\n<\/tr>\n
A4233<\/td>\nMethylprednisolone<\/td>\n83-43-2<\/td>\n99.31%<\/td>\nApoptosis inducer,GR agonist<\/td>\n<\/tr>\n
A4234<\/td>\nTW-37<\/td>\n877877-35-5<\/td>\n98.13%<\/td>\nBcl-2 inhibitor, inhibits Bcl-2,Bcl-XL and Mcl-1<\/td>\n<\/tr>\n
A4237<\/td>\nAmuvatinib (MP-470, HPK 56)<\/td>\n850879-09-3<\/td>\n99.91%<\/td>\nTyrosine kinase inhibitor<\/td>\n<\/tr>\n
A4240<\/td>\nAbiraterone<\/td>\n154229-19-3<\/td>\n99.30%<\/td>\nPotent CYP17 inhibitor<\/td>\n<\/tr>\n
A4300<\/td>\nGW9662<\/td>\n22978-25-2<\/td>\n99.25%<\/td>\nPPAR\u03b3 antagonist<\/td>\n<\/tr>\n
A4301<\/td>\nT0070907<\/td>\n313516-66-4<\/td>\n99.88%<\/td>\nHuman PPAR\u03b3 antagonist,potent and selective<\/td>\n<\/tr>\n
A4302<\/td>\nRosiglitazone maleate<\/td>\n155141-29-0<\/td>\n99.15%<\/td>\nPPAR\u03b3 agonist,high-affinity and selective,potent insulin sensitizer<\/td>\n<\/tr>\n
A4303<\/td>\nGSK3787<\/td>\n188591-46-0<\/td>\n99.73%<\/td>\nPPAR\u03b2\/\u03b4 antagonist,novel and irreversible<\/td>\n<\/tr>\n
A4304<\/td>\nRosiglitazone<\/td>\n122320-73-4<\/td>\n99.80%<\/td>\nPotent PPAR\u03b3 agonist<\/td>\n<\/tr>\n
A4305<\/td>\nWY-14643 (Pirinixic Acid)<\/td>\n50892-23-4<\/td>\n99.87%<\/td>\nPPAR\u03b1 agonist,selective and highly potent<\/td>\n<\/tr>\n
A4306<\/td>\nCiprofibrate<\/td>\n52214-84-3<\/td>\n98.88%<\/td>\nPPAR\u03b1 agonist<\/td>\n<\/tr>\n
A4307<\/td>\nGW0742<\/td>\n317318-84-6<\/td>\n99.64%<\/td>\nPPAR\u03b4\/\u03b2 agonist,potent and selective<\/td>\n<\/tr>\n
A4308<\/td>\nAlizarin<\/td>\n72-48-0<\/td>\n98.03%<\/td>\nChelator for calcium,used to stain calcium deposites,Alizarin complexone is used for bone staining to study bone remodeling<\/td>\n<\/tr>\n
A4309<\/td>\nGW501516<\/td>\n317318-70-0<\/td>\n98.27%<\/td>\nPPAR\u03b4 agonist,selective and potent<\/td>\n<\/tr>\n
A4310<\/td>\nRosiglitazone HCl<\/td>\n302543-62-0<\/td>\n99.31%<\/td>\nPPAR\u03b3 agonist<\/td>\n<\/tr>\n
A4311<\/td>\nPF-4981517<\/td>\n1390637-82-7<\/td>\n98.00%<\/td>\nCYP3A4 inhibitor,potent and selective<\/td>\n<\/tr>\n
A4313<\/td>\nCobicistat (GS-9350)<\/td>\n1004316-88-4<\/td>\n99.94%<\/td>\nSelective CYP3A inhibitor<\/td>\n<\/tr>\n
A4316<\/td>\nKetoconazole<\/td>\n65277-42-1<\/td>\n99.48%<\/td>\nInhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase<\/td>\n<\/tr>\n
A4317<\/td>\nApremilast (CC-10004)<\/td>\n608141-41-9<\/td>\n98.98%<\/td>\nPDE4 inhibitor<\/td>\n<\/tr>\n
A4318<\/td>\nAvasimibe<\/td>\n166518-60-1<\/td>\n99.66%<\/td>\nACAT inhibitor,orally bioavailable<\/td>\n<\/tr>\n
A4319<\/td>\nRoflumilast<\/td>\n162401-32-3<\/td>\n99.08%<\/td>\nPDE-4 inhibitor<\/td>\n<\/tr>\n
A4320<\/td>\nVoriconazole<\/td>\n137234-62-9<\/td>\n99.96%<\/td>\nCYP51 inhibitor<\/td>\n<\/tr>\n
A4321<\/td>\nSildenafil Citrate<\/td>\n171599-83-0<\/td>\n99.63%<\/td>\nTreat erectile dysfunction and PAH<\/td>\n<\/tr>\n
A4322<\/td>\nClarithromycin<\/td>\n81103-11-9<\/td>\n99.39%<\/td>\nCYP3A inhibitor, potent<\/td>\n<\/tr>\n
A4323<\/td>\nVardenafil HCl Trihydrate<\/td>\n330808-88-3<\/td>\n99.63%<\/td>\nPDE5 inhibitor, potent and selective<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

\u03b2-\u5167\u91af\u80fa\u985e\u6297\u751f\u7d20\u7cfb\u5217\u5546\u54c1->>\u5b89\u6bd4\u897f\u6797Ampicillin sodium APExBIO Tec […]<\/p>\n","protected":false},"author":3,"featured_media":34209,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5368,486],"tags":[4949],"_links":{"self":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34208"}],"collection":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34208"}],"version-history":[{"count":7,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34208\/revisions"}],"predecessor-version":[{"id":53716,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/34208\/revisions\/53716"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/34209"}],"wp:attachment":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}